Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-41355

Sharps Technology, Inc.

(Exact name of registrant as specified in its charter)

Nevada

82-3751728

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

105 Maxess Road, Melville, New York 11747

(Address of principal executive offices) (Zip Code)

(631) 574 -4436

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	STSS	NASDAQ Capital Market
Common Stock Purchase Warrants	STSSW	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August, 14, 2024, the issuer had 28,590,509 shares of common stock, par value $0.0001 per share, outstanding.

SHARPS TECHNOLOGY, INC.

TABLE OF CONTENTS

		Page No.
PART I FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS (Unaudited)
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statement of Comprehensive Loss	3
	Condensed Consolidated Statements of Stockholders’ Equity	4
	Condensed Consolidated Statements of Cash Flows	6
	Notes to the Condensed Consolidated Financial Statements	7
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	27
ITEM 4.	CONTROLS AND PROCEDURES	28
PART II OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	28
ITEM 1A.	RISK FACTORS	28
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	28
ITEM 6.	EXHIBITS	29
SIGNATURES		30

SHARPS TECHNOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2024			December 31, 2023
	(Unaudited)			(Audited)
Assets:
Current Assets
Cash	$	1,483,293		$	3,012,908
Prepaid expenses and other current assets		162,298			116,508
Inventories, net (Note 3)		1,885,832			1,709,135
Current Assets		3,531,423			4,838,551

Fixed Assets, net of accumulated depreciation (Notes 4 and 5)		6,282,316			6,822,142
Other Assets (Notes 5 and 6)		118,482			128,575
TOTAL ASSETS	$	9,932,221		$	11,789,268

Liabilities:
Current Liabilities
Accounts payable	$	878,048		$	794,107
Accrued and other current liabilities (Notes 12 and 14)		231,313			476,090
Warrant liability (Notes 7 and 9)		1,443,662			2,422,785
Total Current Liabilities		2,553,023			3,692,982

Deferred Tax Liability		162,000			162,000
Total Liabilities		2,715,023			3,854,982

Commitments and Contingencies (Note 14)		-			-

Stockholders’ Equity:
Preferred stock, $.0001 par value; 1,000,000 shares authorized; 1 share issued and outstanding		-			-
Common stock, $.0001 par value; 100,000,000, shares authorized; 28,590,509 shares issued and outstanding (2023: 15,274,457)		2,860			1,528
Additional paid-in capital		35,096,207			32,489,950
Accumulated other comprehensive income		351,848			591,812
Accumulated deficit		(28,233,717	)		(25,149,004	)
Total Stockholders’ Equity		7,217,198			7,934,286
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	9,932,221		$	11,789,268

The accompanying notes are an integral part of these financial statements.

SHARPS TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE

(UNAUDITED)


	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2024			2023			2024			2023
Revenue, net	$	-		$	-			-			-

Operating expenses:
Research and development		180,297			224,260			377,736			558,148
General and administrative		1,740,803			2,308,075			3,387,416			4,291,987
Total operating expenses		1,921,100			2,532,335			3,765,152			4,850,135
Loss from operations		(1,921,100	)		(2,532,335	)		(3,765,152	)		(4,850,135	)

Other income (expense)
Other (expense) income (Note 14)		(994,712	)		40,079			(975,688	)		76,871
FMV adjustment on contingent stock & warrants		822,130			(90,108	)		1,672,187			93,977
Foreign currency		(8,645	)		(23,461	)		(16,060	)		(38,368	)
Total Other Income (Expense)		(181,227	)		(73,490	)		680,439			132,480
Net Loss	$	(2,102,327	)	$	(2,605,825	)		(3,084,713	)		(4,717,655	)

Net loss per share, basic and diluted	$	(0.10	)	$	(0.22	)		(0.15	)		(0.42	)
Weighted average shares used to compute net loss per share, basic and diluted		21,557,563			11,655,936			20,106,750			11,193,740

The accompanying notes are an integral part of these financial statements.

SHARPS TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30

(UNAUDITED)


	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2024			2023			2024			2023
Net loss	$	(2,102,327	)	$	(2,605,825	)		(3,084,713	)		(4,717,655	)

Other comprehensive income:

Foreign currency translation adjustments gain/(loss)		(21,911	)		73,786			(239,964	)		344,859

Comprehensive loss	$	(2,124,238	)	$	(2,532,039	)		(3,324,677	)		(4,372,796	)

The accompanying notes are an integral part of these financial statements.

SHARPS TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024

(Unaudited)

	Shares		Amount		Shares		Amount			Capital		Income			Deficit			Equity
	Preferred Stock				Common Stock					Additional Paid in		Accumulated Other Comprehensive			Accumulated			Total Stockholders
	Shares		Amount		Shares		Amount			Capital		Income			Deficit			Equity

Balance -December 31, 2023		1	$	-		15,274,457	$	1,528	-	$	32,489,950	$	591,812		$	(25,149,004	)	$	7,934,286

Net loss for the three months ended March 31, 2024		-		-		-		-	-		-		-			(982,386	)		(982,386	)

Share-based compensation charges		-		-		-		-			126,387		-			-			126,387

Exercise of Pre-Funded Warrants		-		-		396,441		40			356		-			-			396

Foreign Currency Translation		-		-		-		-			-		(218,053	)		-			(218,053	)

Balance - March 31, 2024		1	$	-		15,670,898	$	1,568	-	$	32,616,693	$	373,759		$	(26,131,390	)	$	6,860,630

Net loss for the three months ended June 30, 2024		-		-					-							(2,102,327	)		(2,102,327	)

Share-based compensation charges		-									201,918								201,918

Exercise of Pre-Funded Warrants						2,985,038		298			2,687								2,985
Registration A Offering						4,197,000		420			1,296,502								1,296,922
Warrant Inducements						5,737,573		574			978,407								978,981
Foreign Currency Translation													(21,911	)					(21,911	)

Balance - June 30, 2024		1	$	-		28,590,509	$	2,860	-	$	35,096,207	$	351,848		$	(28,233,717	)	$	7,217,198

SHARPS TECHNOLOGY, INC.

CONDENSED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023

(Unaudited)


	Preferred Stock				Common Stock				Common Stock Subscription		Additional Paid in		Accumulated Other Comprehensive		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Receivable		Capital		Income		Deficit			Equity

Balance -December 31, 2022		1	$	-		9,407,415	$	941		-	$	24,733,306	$	214,253	$	(15,307,366	)	$	9,641,134

Net loss for the three months ended March 31, 2023		-		-		-		-		-		-		-		(2,111,830	)		(2,111,830	)
Shares issued in Offering						2,248,521		225				2,783,160		-					2,783,385
Share-based compensation charges		-		-		-		-		-		383,100		-		-			383,100
Foreign Currency Translation		-		-						-		-		270,983		-			270,983

Balance - March 31, 2023		1	$	-		11,655,936	$	1,166		-	$	27,899,566	$	485,236	$	(17,419,196	)	$	10,966,772
Balance		1	$	-		11,655,936	$	1,166		-	$	27,899,566	$	485,236	$	(17,419,196	)	$	10,966,772

Net loss for the three months ended June 30, 2023		-		-		-		-		-		-		-		(2,605,825	)		(2,605,825	)
Net loss		-		-		-		-		-		-		-		(2,605,825	)		(2,605,825	)
Share-based compensation charges		-		-		-		-		-		254,446		-		-			254,446
Foreign Currency Translation		-		-						-		-		73,876		-			73,876

Balance - June 30, 2023		1	$	-		11,655,936	$	1,166		-	$	28,154,012	$	559,112	$	(20,025,021	)	$	8,689,269
Balance		1	$	-		11,655,936	$	1,166		-	$	28,154,012	$	559,112	$	(20,025,021	)	$	8,689,269

The accompanying notes are an integral part of these financial statements.

SHARPS TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30

(UNAUDITED)


	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,084,713	)	$	(4,717,655	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		388,520			448,657
Stock-based compensation		328,305			637,547
FMV adjustment for Warrants		(1,672,187	)		(93,977	)
Escrow forfeited		1,000,000			-
Foreign exchange gain		(8,646	)		30,141
Changes in operating assets:
Prepaid expenses and other current assets		(49,627	)		(119,761	)
Inventory		(255,439	)		(769,088	)
Other assets		-			-
Accounts payable and accrued liabilities		(174,889	)		453,136
Net cash used in operating activities		(3,528,676	)		(4,131,000	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of fixed assets or deposits paid		(19,355	)		(342,525	)
Escrow payment under agreement		(1,000,000	)		-
Net cash used in investing activities		(1,019,355	)		(342,525	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from offerings and warrant exercises		2,972,348			3,238,711
Net cash provided by financing activities		2,972,348			3,238,711

Effect of exchange rate changes on cash		46,068			(12,064	)

NET INCREASE (DECREASE) IN CASH		(1,529,615	)		(1,246,878	)
CASH — BEGINNING OF YEAR		3,012,908			4,170,897
CASH — END OF PERIOD	$	1,483,293		$	2,924,019

The accompanying notes are an integral part of these financial statements.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 1. Description of Business

Nature of Business and Going Concern

Sharps Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented various safety syringes and is seeking commercialization by manufacturing and distribution of its products.

The accompanying condensed consolidated financial statements include the accounts of Sharps Technology, Inc., and its wholly owned subsidiaries, Safegard Medical, Kft. and Sharps Technology Acquisition Corp. collectively referred to as the “Company.” The condensed consolidated balance sheet as of June 30, 2024 and the condensed consolidated statements of operations, statements of comprehensive loss, statements of stockholders’ equity and the statements of cash flow for three and six months ended June 30, 2024 and 2023 (the “interim statements”) are unaudited. All intercompany transactions and balances have been eliminated. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has not generated revenue or cash flow from operations since inception. As of June 30, 2024, the Company had a working capital of $978,400 which is not expected to be sufficient to fund the Company’s planned operations for the next 12 months. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise sufficient financing to acquire or commercialize its products into a profitable business. The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The unaudited condensed consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company’s fiscal year ends on December 31.

On April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company received net proceeds of $14.2 million on April 19, 2022 (See Note 7).

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As of June 30, 2024, the most significant estimates relate to derivative liabilities and stock-based compensation.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original or remaining maturity of six months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions. At June 30, 2024 and December 31, 2023, the Company had no cash equivalents.

Inventories

The Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess or obsolete inventories or they may be written off. At June 30, 2024, and December 31, 2023, inventory is comprised of raw materials, including packaging, work in process (components) and finished goods.

Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value.

The Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating results at the reporting periods.

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.

Level 2

Level 2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates, maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed most similar to the security being priced; and determining whether a market is considered active requires management judgment.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Level 3

Level 3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.

Fixed Assets

Fixed assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20 years, Machinery and Equipment – 3 - 10 years and Website and Computer Systems – 3 years. The expected life for Molds is based on the lesser of the number of parts that will be produced based on the expected mold capability or 5 years.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.

There were no impairment losses recognized during the three and six months ended June 30, 2024 and 2023.

Purchased Identified Intangible Assets

The Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying value of indefinite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.

Stock-based Compensation Expense

The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur on a prospective basis.

Stock-based compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Derivative Instruments

The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

At their issuance date and as of June 30, 2024, certain warrants (see Notes 7 and 9) were accounted for as liabilities as these instruments did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value is recognized in the Company’s condensed consolidated statements of operations.

Foreign Currency Translation/Transactions

The Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the condensed consolidated statements of operations.

Comprehensive income (loss)

Comprehensive income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary. Foreign currency translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance at June 30, 2024 and December 31, 2023. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments.

Basic and Diluted Loss Per Share

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the consolidated statements of operations. Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of June 30, 2024, there were 24,451,943 stock options and warrants that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Income Taxes

The Company must make certain estimates and judgments in determining income tax expenses for financial statement purposes. These estimates and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision in a subsequent period.

The provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities. The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in the period of such change.

Research and Development Costs

Research and development costs are expensed as incurred.

Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the services are performed.

Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.

Recent Accounting Pronouncements

On August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company does not expect the pronouncement to have a material impact on the Company and will disclose the nature and reason for any elections that the Company makes.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires disaggregated information about the effective tax rate reconciliation and additional information on taxes paid that meet a quantitative threshold. The new guidance is effective for public companies for annual reporting periods beginning after December 15, 2024, a, with early adoption permitted. The Company is currently evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements.

The Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial statements.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Note 3. Inventories

Inventories, net consisted of the following at:

	June 30, 2024		December 31, 2023
Raw materials	$	302,107	$	254,461
Work in process		116,148		170,464
Finished goods		1,467,577		1,284,210
Total	$	1,885,832	$	1,709,135

Note 4. Fixed Assets

Fixed assets, net, is summarized as follows as of:

	June 30, 2024			December 31, 2023

Land	$	246,075		$	260,460
Building		2,866,164			3,022,490
Machinery and Equipment		4,663,594			4,464,317
Computer Systems and Website & Other		290,662			290,661
Total Fixed Assets		8,066,495			8,037,928
Less: accumulated depreciation		(1,784,179	)		(1,215,786	)
Fixed asset, net	$	6,282,316		$	6,822,142

Depreciation expense of fixed assets for the six months ended June 30, 2024 and 2023 was $378,636 and $445,252, respectively. Substantially, all the Company’s fixed assets are located at the Company’s Hungary location.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 5. Asset Acquisition

Safegard Medical, Kft

In June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical, Kft (“Safegard”) and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain assets of a manufacturing facility for $2.5M in cash, plus additional consideration of of common stock and options with a fair market value of $200,000 and $183,135, respectively. The Agreements provided the Company various periods for due diligence and post due diligence, requirements for escrow payments through the closing date (“Closing Date”).

Through the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.

The acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10, and accordingly was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the acquisition was $2,936,712, including transaction costs of $53,576, with the allocation to the assets acquired on a relative fair value basis. The intangibles relate to permits and a limited workforce acquired. Under ASC 805-50, no goodwill is recognized. The operating results for Safegard are included in the condensed consolidated financial statements for the period beginning after the closing on July 6, 2022.

The relative fair value of the assets acquired and related deferred tax liability during 2022 was as follows:


Land	$	226,000
Building and affixed assets		2,648,000
Machinery		158,000
Inventory		32,000
Intangibles		64,712
Deferred tax liability		(192,000	)

Total	$	2,936,712

The useful lives for the acquired assets is Building - 20 years; Machinery – 5 to 10 years; Intangibles – 5 years. The related depreciation and amortization is being recorded on a straight-line basis.

Note 6. Other Assets

Other assets as of June 30, 2024 and December 31, 2023 are summarized as follows:

	June 30, 2024		December 31, 2023

Intangibles, net		42,420		52,513
Other		76,062		76,062
Total Other assets	$	118,482	$	128,575

Note 7. Stockholders’ Equity

Capital Structure

On December 11, 2017, the Company was incorporated in Wyoming with 20,000,000 shares of common stock authorized with a $0.0001 par value. Effective, April 18, 2019, the Company’s authorized common stock was increased to 50,000,000 shares of common stock. The articles of incorporation also authorized 10,000 preferred shares with a $0.001 par value.

Effective March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps Nevada”). Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation. The Company’s authorized common stock and preferred stock increased from 50,000,000 to 100,000,000 and 10,000 to 1,000,000 shares, respectively. The par value of preferred stock decreased from $0.001 to $0.0001 per share.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 7 Stockholders’ Equity (continued)

Common Stock

On May 31 and June 13, 2024, the Company entered into subscription agreements with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors 4,197,000 shares (the “Shares”) of Common Stock, par value $0.0001 per share of the Company at a price of $0.38 and received gross proceeds to the Company of $1.6M before expenses to the placement agent and other offering expenses of $298,000 with net proceeds, after reflecting par value, have been recorded in Additional Paid in Capital of $1,296,922. The shares issued in the offering were offered at-the-market under Nasdaq rules and pursuant to the Company’s Form 1-A (the “Offering Statement”), initially filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended on May 21, 2024, and qualified on May 30, 2024.

On May 30, 2024, the Company offered warrant inducements (the “Inducement Agreement”) to certain warrant holders (the “Warrant Holders”) which references the warrants registered for sale under both the registration statements on Form S-1 (file No. 333-263715) and/or the registration statement on Form S-1 (File No. 333-275011) (collectively, the “Registration Statements”) for up to a total of 10,998,524 warrants to purchase shares of the Company’s common stock, par value $0.0001 per share. Pursuant to the Inducement Agreement, the exercise price of the existing warrants was reduced from $0.64 per share to $0.33 per share. In addition, for each warrant that was exercised, as a result of the Inducement Agreement, the Company agreed to issue the Warrant Holders unregistered warrants with an exercise price of $0.45 per share (“Inducement Warrants”). In the aggregate, 5,737,573 warrants were exercised as a result of the Inducement Agreement and accordingly, 5,737,573 Inducement Warrants were issued. The Company received gross proceeds of $1.9M before expenses to the placement agent and other expenses of $285,000. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $978,407 and with respect to the Inducement Warrants, a liability under ASC 815 was recorded in the amount of $693,064. Certain outstanding warrants, with an exercise price of $0.64, were reduced to $0.33 based on anti-dilution terms in the respective warrant agreements.

The Company recorded a fair value charge in the three months and six months ended to reflect the modification of the exercise price at the initial inducement date for the non-trading warrants relating to the February and September 2023 warrants below. (See Note 9)

On September 29, 2023, the Company completed two simultaneous offerings and received aggregate gross proceeds of approximately $5.6 million, before expenses to the placement agent and other offering expenses of $716,000.

The first offering, the securities purchase agreement offering (the “Shelf Offering”) with institutional investors and the Company resulted in the Company receiving net proceeds from the Shelf Offering and the sale of pre-funded of approximately $2.5 million, includes the value of the pre-funded warrants recorded in APIC, net of $362,000 in fees relating to the placement agent and other offering expenses. The Shelf Offering was priced at the market under Nasdaq rules. In connection with the Shelf Offering, the Company issued 3,618,521 shares of common at a purchase price of $064 per unit, adjusted to $0.33 at May 30, 2024, based on anti-dilution terms in the warrants and 800,000 pre-funded warrants at $0.639 per pre-funded warrants. The exercise price of the pre-funded warrants will be $0.001 per share.

The second offering, the securities purchase agreement offering (“Private Placement”) with institutional investors and the Company received net proceeds from the Private Placement of approximately $2.4 million, net of $354,000 in fees relating to the placement agent and other offering expense. In connection with the Private Placement, the Company issued: (i) 2,581,479 PIPE Shares (or PIPE Pre-Funded Warrants in lieu thereof) and (ii) PIPE Warrants (non-trading) to purchase 8,750,003 shares of our common stock, at a combined purchase price of $1.074 per unit (or $1.073 per pre-funded unit). The PIPE Warrants have a term of five and one-half (5.5) years from the issuance date and are exercisable for one share of common stock at an exercise price of $0.64 adjusted to $0.33 at May 30, 2024, based on anti-dilution terms in the warrants. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $1.6 million and with respect to the PIPE Warrants recorded as a liability under ASC 815 of $985,204. On October 16, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Private Placement and on October 26, 2023 the S-1 went effective. (See Note 9).

During the quarter ended June 30, 2024, the remaining 2.9M pre-funded warrants from the aforementioned September 2023 offerings were exercised and, after reflecting par value, Additional Paid in Capital of $2,686 was recorded.

On February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and received net proceeds from the Offering of approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, the Company issued 2,248,521 units at a purchase price of $1.69 per unit. Each unit consisted of one share of common stock and one non-tradable warrant (“Offering Warrants”) exercisable for one share of common stock at a price of $1.56, adjusted to $0.64 at September 29, 2023 and to $0.33 at May 30, 2024, based on anti-dilution terms in the warrants and a term of five years. The Offering Warrants have a term of five years from the issuance date. On February 13, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Offering and on April 14, 2023, an Amendment to the S-1 was filed and went effective. (See Note 9)

On April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the Company issued and sold an aggregate of 3,750,000 units (“Units”), each consisting of one share of common stock and two warrants, to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share, adjusted to $1.56 at February 3, 2023 and to $0.64 at September 29, 2023 and to $0.33 at May 30, 2024, based on anti-dilution terms in the warrants, and a term of five years. In addition, the Company granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number of shares included in the units sold in the offering, and/or additional warrants equal to 15% of the number of Warrants included in the units sold in the offering, in each case solely to cover over-allotments, which the Aegis Capital Corp. partially exercised with respect to 1,125,000 warrants on April 19, 2022.

The Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds from the IPO, prior to payments of certain listing and professional fees were approximately $14.2 million. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $9.0 million and with respect to the Warrants as a liability under ASC 815 of $5.2M. (See Note 9)

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 7. Stockholders’ Equity (continued)

Warrants

	a)	In connection with the Inducement Warrants in the second quarter of 2024, the Company issued 5,737,573 non-trading Inducement Warrants as noted in Common Stock above. The Inducement Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The Inducement Warrants are recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024, the Company recorded a FMV gain adjustment of $293,684 (See Note 9).

	b)	In connection with one-year advisory services arrangement entered into in April 2023, the Company issued an aggregate of 630,000 warrants over the one-year term, at an exercise price of $1.56. During the three and six months ended June 30, 2024, the Company issued 0 and 135,000 warrants with a FMV of $8,590. During the three and six months ended June 30, 2023 the Company issued 135,000 warrants with a FMV of $19,836. The warrants have a three-year term and were fully vested on issuance. The FMV of the warrants issued in the six months ended June 30, 2024 was computed using the Black Scholes valuation model with the following assumptions: a) volatility of 33.46% to 81.62%, three-year term, risk free interest rate of 4.20% to 4.25% and 0% dividend rate. The FMV of the warrants issued in the three and six months ended June 30, 2023 was computed using the Black Scholes valuation model with the following assumptions: a) volatility of 37.45%, risk free interest rate of 3.58% and 0% dividend rate (See Note 9).

	c)	In connection with the Private Placement in September 2023, the Company issued 8,750,003 non-trading PIPE Warrants as a component of the Unit as noted in Common Stock above. The PIPE Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The PIPE Warrants are recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024, the Company recorded a FMV gain adjustment of $326,580, including the modification charge of $489,225 and $651,884, respectively (See Note 9).

	d)	In connection with the Offering in February 2023, the Company issued 2,248,521 non-trading warrants Offering Warrants as a component of the Unit as noted in Common Stock above. The Offering Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The Offering Warrants were recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024 the Company recorded FMV gain adjustments of $139,844, including the modification charge of 146,028 referred to in Note 8 and $221,582, respectively For the three and six months ended June 30, 2023, the Company recorded a FMV gain (loss) of $(1,505) and $182,580 respectively (See Note 9).

	e)	In connection with the IPO in April 2022, the Company issued 7,500,000 warrants (Trading Warrants) as a component of the Units and 1,125,000 warrants to the underwriter (Overallotment Warrants), as noted in Common Stock above. The Trading and Overallotment Warrants were recorded at the FMV, being the trading price of the warrants, on the IPO effective date and the Warrants are classified as a Liability based on ASC 815. The Warrant liability requires remeasurement at each reporting period based on the trading price of the warrants. During the three and six months ended June 30, 2024, the Company recorded an FMV gain adjustment of $60,375 and $491,625, respectively. For the three and six months ended June 30, 2023, the Company recorded a FMV loss of $86,250 (See Note 9).

	(f)	The Company issued 235,295 Warrants (“Note Warrants”) to the note holders in connection with the repayment on the IPO on April 19, 2022. The Note Warrants, which are recorded at the FMV being the trading price of the warrants, are classified as a Liability based on ASC 815. The Note Warrants require remeasurement at each reporting period. During the three and six months ended June 30, 2024, the Company recorded a FMV gain of $1,647 and $13,412, respectively. For the three and six months ended June 30, 2023, the Company recorded a FMV loss of $2,353 (See Note 9).

	(g)	The underwriter received 187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price of $5.32 and are exercisable after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Scholes valuation model with the following assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend rate. The estimated FMV was classified as additional issuance costs.

Note 8 Preferred Stock

In February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder and Director. The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced from 50.1% at December 31, 2021 to 29.5%, effective with the IPO. The Series A Preferred Stock has no right to dividends, or distributions in the event of a liquidation and is not convertible into common stock. In connection with the settlement with Mr. Blackman, once the final payment occurs at the end of August 2024, the Series A Preferred Stock shall be deemed immediately cancelled and forfeited and without further consideration. The Series A Preferred shall at such time be returned to the status of an authorized but unissued share of preferred stock of the Company (See Note 14).

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 9. Warrant Liability

Certain Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the condensed consolidated statements of operations. The Black Scholes Option-Pricing model used the following assumptions for the six months ended June 30, 2024 and 2023 (See Note7).

Schedule of Fair Value of Warrant

	June 30, 2024			June 30, 2023
Expected term (years)		3.90 to 5.59			3.00 to 3.86
Expected volatility		58.78% to 68.05	%		37.45% to 45.21	%
Risk-free interest rate		4.10% to 4.56	%		3.53% to 3.58	%
Dividend rate		0			0

The Warrant liability at June 30, 2024 and December 31, 2023 was as follows:

Schedule of Warrant Liability

	June 30, 2024		December 31, 2023
Trading and Overallotment Warrants	$	629,625	$	1,121,250
Note Warrants		17,176		30,588
Offering Warrants – February 2023		12,490		234,072
Offering Warrants – September 2023		384,991		1,036,875
Inducement Warrants – May 2024		399,380		-
Total Warrant Liability	$	1,443,662	$	2,422,785

The Warrants outstanding at June 30, 2024 and December 31, 2023 were as follows:

Schedule of Warrant Outstanding

	June 30, 2024		December 31,2023

Trading and Overallotment Warrants		8,812,500		8,812,500
Note Warrants		235,295		235,295
Offering Warrants – February 2023		189,349		2,248,521
Offering Warrants – September 2023		5,071,602		8,750,003
Inducement Warrants – May 2024		5,737,573		-
Warrants issued for services arrangement		630,000		495,000
Total Warrants Outstanding		20,676,319		20,541,319

For the three and six ended June 30, 2024, the FMV gain adjustment, which is reflected in the FMV adjustment on Warrants in the Unaudited Condensed Consolidated Statements of Operations was $822,130, which includes the modification charge of $635,253 for the warrants exercised in connection with the Inducement Agreements and $1,672,187 respectively (See Note 7).

For the three and six months ended June 30, 2023, the FMV loss adjustment, which is reflected in the FMV adjustment gain (loss) on Warrants in the Unaudited Condensed Consolidated Statements of Operations was $(90,108) and $93,977, respectively (see Note 7).

Note 10. Stock Options

A summary of options granted and outstanding is presented below.

	June 30, 2024
	Options			Weighted Average Exercise Price
Outstanding at Beginning of year		2,408,836		$	3.03
Granted		1,357,000			.28
Forfeited		(8,214	)		3.42
Outstanding at end of period		3,775,621		$	1.99

Exercisable at end of period		2,784,399		$	2.56

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 10 Stock Options (continued)

At June 30, 2024, the Weighted Average Remaining Contractual Life is forty-six months.

At June 30, 2024, the stock options outstanding and the options exercisable have exercise prices that exceed the stock market price at June 30, 2024 and as such no intrinsic value exists. Intrinsic value is defined as the difference between the exercise price of the options and the market price of the Company’s common stock.

During the six months ended June 30, 2024, the Company granted five-year options (the “Options”) to purchase a total of 1,357,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to its directors, executive officers, employees and consultants pursuant to the Company’s. 2023 Equity Incentive Plans. The Options are exercisable at $0.285 per share which was the closing price on grant date April 26, 2024.

As of June 30, 2024, there was $355,730 of unrecognized stock-based compensation related to unvested stock options with a weighted average fair value of $0.93 per share, which is expected to be recognized over a weighted-average period 11 months as of June 30, 2024.

For the three and six months ended June 30, 2024, the Company recognized stock-based compensation expense of $201,918 and $319,715 respectively, of which $316,374 and $3,341 was recorded in general and administrative and research and development expenses, respectively.

For the three and six months ended June 30, 2023, the Company recognized stock-based compensation expense of $234,610 and $617,711 which was recorded in general and administrative.

The fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions for the options granted during the six months ended June 30, 2024 and 2023.

	June 30, 2024			June 30, 2023
Expected term (years)		2.66 to 3.06			2.77 to 3.25
Expected volatility		81.15% to 83.04	%		75.40% to 89.93	%
Risk-free interest rate		4.71% to 4.76	%		3.74% to 4.27	%
Dividend rate		0			0

Note 11. Income Taxes

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three and six months ended June 30, 2024 and 2023 was 0% The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 12. Related Party Transactions and Balances

As of June 30, 2024 and December 31, 2023, accounts payable and accrued liabilities include $114,000 and $32,974, respectively, payable to officers and directors of the Company. The amounts are unsecured, non-interest bearing and are due on demand.

Note 13. Fair Value Measurements

The Company’s financial instruments include cash, accounts payable, and warrant liability. Cash and warrant liability are measured at fair value. Accounts payable is measured at amortized cost and approximates fair value due to its short duration.

As of June 30, 2024, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:

	Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	1,483,293		-		-	$	1,483,293

Total assets measured at fair value	$	1,483,293		-		-	$	1,483,293

Liabilities
Warrant liability	$	-	$	1,443,662		-	$	1,443,662

Total liabilities measured at fair value	$	-	$	1,443,662			$	1,443,662

As of December 31, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:


	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	3,012,908		-		-	$	3,012,908

Total assets measured at fair value	$	3,012,908		-		-	$	3,012,908

Liabilities
Warrant liability	$	-	$	2,422,785		—	$	2,422,785

Total liabilities measured at fair value	$	-	$	2,422,785		-	$	2,422,785

Note 14. Commitments and Contingencies

Contingencies

At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently not involved in any material litigation or other loss contingencies.

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 14 Commitments and Contingencies (continued)

Commitments

On August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and entered into an Employment Agreement. which provided for annual salary of $256,000, which provides for increases, and provisions compensation adjustments, expense and tax differential reimbursements, benefits and bonuses. As of September 1, 2022, the annual salary is $320,000. At June 30, 2022, the Company approved and accrued a $250,000 bonus to Mr. Blackman for services provided in 2022, of which $65,000 was paid subsequent to December 31, 2022. The Company terminated Mr. Blackman’s Employment Agreement effective May 1, 2023. Mr. Blackman continued to serve as the Co-Chairman and a member of the Board of Directors. Subsequent to June 30, 2023, the Company and Mr. Blackman entered into a separation agreement whereby, Mr. Blackman will be paid severance payments of approximately $346,000, which was recorded as an expense and an accrued expense as of June 30, 2023, over thirteen months, continue his medical benefits for such period with a cost of approximately $29,000 which has been accrued at June 30, 2023. Further, all unvested options were fully vested, and the Company recorded a charge of $60,000 in 2023. At June 30, 2024, the outstanding balance due Mr. Blackman is $53.000, which will be paid by August 31, 2024. In connection with the separation agreement, Mr. Blackman no longer serves as Co-Chairman or Board member and has agreed to vote his Series A Preferred Stock in favor of the election, reelection, and/or designation of each individual nominated to serve as a director on the Board of Director as shall be identified in an applicable proxy statement filed by the Company for such election of directors. Once the payments due Mr. Blackman are fully paid, the Series A Preferred Stock shall be deemed immediately cancelled and forfeited and without further consideration. The Series A Preferred shall at such time be returned to the status of an authorized but unissued share of preferred stock of the Company.

On September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until terminated by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the Company’s Chief Financial Officer on a contract services basis for the last three years. The agreement provided for annual compensation of $225,000 and plus a one-time $18,750 incentive payment upon the commencement of the agreement. During the course of the term, Mr. Crescenzo will be eligible for (i) performance bonuses to be granted at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s 2022 Equity Incentive Plan. The agreement contains customary employment terms and conditions.

On May 20, 2024, the Company entered into an amendment to the Asset Purchase agreement (“Asset Purchase”) with InjectEZ, LLC (“Seller”) for the purchase of certain assets for $35M. In connection with the Asset Purchase agreement the Company paid a non-refundable deposit of $1M to be held in escrow under an agreeable escrow agreement as a deposit on the purchase price. The Asset Purchase agreement stipulated that the $1M deposit would be maintained until July 19, 2024, at which date, if the contemplated transaction was not consummated, through no fault of the Seller, the escrow would be released to the Seller by the escrow agent. The escrow deposit of $1M was released to the Seller and recorded a forfeited agreement cost in Other Expenses in the three months and six months ended June 30, 2024. The Company and Seller are currently working towards a further amendment of the Asset Purchase Agreement and expect to achieve a positive outcome in the near term. The closing of the Asset Purchase Agreement is contingent on obtaining the necessary financing and there can be no assurance that the closing of the asset sale will occur.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of our Company as of and for the periods presented below. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to Sharps Technology, Inc.

Forward-Looking Statements

The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.

Overview

Since our inception in 2017, we have devoted substantially all our resources to the research and development and commencing the latter part of 2023 on manufacturing of our safety syringe products. To date, we have not generated any significant revenues from sale of syringe products. We have incurred net losses in each year since our inception and, as of June 30, 2024, we had an accumulated deficit of $28,233,717. Our net loss was $3,084,713 for the six months ended June 30, 2024. Substantially all of our net losses resulted from costs incurred in connection with our research and development efforts, payroll and consulting fees, stock compensation and general and administrative costs associated with our operations, including costs incurred for being a public company since April 14, 2022. See below, Liquidity and Capital Resources and Notes to Unaudited Condensed Consolidated Financial Statements.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has not generated any significant revenue from sale of syringe products or cash flow from operations since inception. As of June 30, 2024, the Company had working capital of $978,400 which is not expected to be sufficient to fund the Company’s planned operations for the next 12 months. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise sufficient financing to acquire or commercialize its products into a profitable business. The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

We classify our operating expenses as research and development and general and administrative expenses. We maintain a corporate office located in Melville, New York, but employees and consultants in the US work remotely and will continue to do so indefinitely. In June 2020, we entered into an agreement to acquire Safegard Medical (Safegard), a former syringe manufacturing facility in Hungary. Through the closing on July 6, 2022, we were contractually provided the exclusive use of the facility for research and development and testing in exchange for payment of the seller’s operating costs, including among others, use of Safegard’s work force, utility costs and other services.

In order to compete in the market, we must maintain inventory. Commencing in the 4^th Quarter of 2022 we started building inventory. We require commercial quantities of inventory to secure orders. Delivery is expected shortly after receiving orders.

Although we currently have production capacity for our products and thus the ability to receive and fulfill orders, we have used the proceeds from the February 2023, September 2023 fund raising and fund raising in the second quarter of 2024 to allow us to further increase our production capacity, build inventory and support working capital requirements This will help us to generate and fulfill orders for our current product line and advance our new innovative products in connection with recent collaboration arrangements. We are currently continuing to produce commercial quantities of our products and building inventory to support the Sales and Distribution Agreement with Roncadelle, in anticipation of receiving additional orders in 2024. (See Recent Developments)

Products, Marketing and Sales

We continue to be in discussions with healthcare companies and distributors for sales of our disposable syringe and prefillable syringe products. We intend to market these products to the U.S. and foreign governments and we received a Purchase Order for our first Securegard sales to a South America distributor which was shipped in June 2024. We will also look to sell our disposable syringe products to hospitals and clinician offices as opportunities present themselves.

The Sharps Securegard product line continues to represent our initial disposable syringe platform to be commercially available to the market. The addition of the Sologard products and SafeR products from Roncadelle are recent expansions to the Company’s product portfolio. These platforms have advanced features and benefits to support the needs of the market along with a high level of readiness for manufacturing and the ability to provide large commercial quantities for customers.

As previously disclosed, there continues to be delays in the commercialization of the Sharps Provensa product line. The product’s specialized technology requires further design and assembly optimization as identified in our previous commercialization efforts. This on-going product refinement process is typical with the development of new technology for the healthcare market to ensure the products are safe and effective for use every time. At this time Sharps is not able to determine a timeline for final commercialization of the Provensa product.

Research and Development

Research and development expense consists of expenses incurred while performing research and development activities for our various syringe products. We recognize research and development expenses as they are incurred. Our research and development expense primarily consist of:

●	Manufacturing and testing costs and related supplies and materials;

●	Consulting fees paid to consultants

●	Operating costs that were paid to Safegard, through the acquisition date for use of Safegard’s workforce, utilities and other services, relating to the facility being utilized; and

●	Third-party costs, including engineering, incurred for development and design.

Substantially all of our research and development expenses to date have been incurred in connection with our syringe products. We expect to continue to incur research and development expenses for the foreseeable future as we continue to enhance our product to meet the market requirements for our Sharps syringe product line for its various intended uses throughout the world.

Business Developments:

On September 29, 2022, the Company entered into an agreement (the “NPC Agreement”) with Nephron Pharmaceuticals Corporation (“NPC”) and various affiliates of NPC, including InjectEZ, LLC. The NPC Agreement intended to support several areas of the Company’s development and growth. The Company and NPC intended to supplement the NPC Agreement by entering into a manufacturing supply agreement, a sales and distribution agreement and a pharma services program to support growth, and a future agreement to support manufacturing expansion. As noted below, the sales and distribution agreement was terminated on March 8, 2024 and replaced. The original manufacturing supply agreement, noted above, will be replaced as part of the Asset Purchase Agreement, entered into on September 22, 2023 (see below) and the Pharma Services agreement continues to be in place, but no activities have occurred to date. The Company will continue working to amend the terms of this NPC Agreement. based on the below Amended Asset Purchase Agreement dated May 20, 2024.

The Pharma Services Program (PSP) with Nephron is intended to create new business development growth opportunities for both companies. These opportunities will include the development and sale of next generation drug delivery systems that will be produced by the Company and can be purchased by the healthcare industry, pharmaceutical markets, as well as by Nephron.

On September 29, 2022, the Company also entered into an agreement (the “Nephron Agreement”) with InjectEZ, LLC (“InjectEZ”), Nephron Pharmaceuticals Corporation (“NPC”), Nephron SC, Inc. (“NSC”), and Nephron Sterile Compounding Center LLC (“Sterile”) (NPC, NSC, and Sterile are sometimes collectively referred to as “Nephron”), pursuant to which Sharps was to provide technical advice and assistance to support manufacturing by InjectEZ, purchase certain quantities of syringes as they may order or require, and collaborate with Nephron on certain related business endeavors. The Company is currently working to further extend the terms of the Nephron Agreement based on the below May 20, 2024 Asset Purchase Agreements.

On September 22, 2023, the Company entered into a series of agreements with Nephron and Nephron’s wholly owned subsidiary InjectEZ, LLC. The Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) to purchase certain equipment and leasehold improvements at Nephron’s facility (the “Facility”) in West Columbia, South Carolina. The Company continues to work with Nephron towards the purchase of the Nephron facility pursuant to the Asset Purchase Agreement dated September 22, 2023. This Asset Purchase Agreement, when closed, will supersede the manufacturing and supply agreement entered into in connection with the NPC Agreement on September 29, 2022, as noted in the subsequent paragraph. The closing of the Asset Purchase Agreement is contingent on obtaining the necessary financing and there can be no assurance that the closing of the asset sale will occur.

On March 4, 2024 (the “Effective”) Company entered into a cooperative sales and distribution agreement (the “Agreement”) with Roncadelle Operations s.r.l (“Roncadelle”). In conjunction with the execution of the note Agreement, Roncadelle appointed the Company as its exclusive distributor of Roncadelle products in the United States, Canada, Central and South America and their territories. The Company appointed Roncadelle as its exclusive distributor of Sharps products in Europe, Middle East, APAC, South Africa and Australia and their territories. The Company and Roncadelle agreed to bear their own separate costs and expenses, including fees and other expenses, relating to external advisors and the preparation negotiation, execution and performance of this Agreement and any related documents. The Agreement is effective as of the Effective Date for the initial period of one (1) year (the “Initial Term”). Upon expiration of the Initial Term, the term of the Agreement shall automatically renew for additional successive one-year terms, unless either party provides written notice of non-renewal at least ninety (90) days prior to the end of the then-current term, unless any renewal term is terminated earlier pursuant to the terms of the Agreement or applicable law.

On March 8, 2024, the Company and Nephron Pharmaceuticals Corporation terminated their distribution agreement dated December 8, 2022. The Nephron distribution agreement has been partially replaced by the aforementioned Agreement with Roncadelle, as stated above, and plans to use other parties to distribute for the US domestic market. The Company entered into a new logistics services agreement on the warehousing side with Owens and Minor (“O&M”) to replace Nephron’s distribution services. The Company had no revenues from the Nephron Distribution Agreement and does not believe that the cancellation is material. The Company is currently negotiating its contract with O&M to provide 3PL services for both the Company and Roncadelle products, in North and South America, beginning in the third quarter of 2024. The Company and Nephron continue to maintain the Pharma Services Program (PSP) that focuses on the creation of new business development and growth opportunities for both companies. These opportunities will include the development and sale of next generation drug delivery systems that will be produced by the Company and can be purchased by the healthcare industry, pharmaceutical markets, and Pharma companies such as Nephron and others.

Recent Business Developments and Updates:

On May 20, 2024, the Company entered into Amendment to the Asset Purchase Agreement dated September 22, 2023 with Nephron and Nephron’s InjectEZ, LLC, collectively, the (Seller”). The Amended Asset Purchase Agreement includes the purchase of certain assets for $35M plus assumed liabilities of $4M, continues to provide for the Company to lease the Facility but excludes any leasehold improvements previously included. In connection with the Asset Purchase agreement the Company paid a non-refundable deposit of $1M to be held in escrow under an agreeable escrow agreement as a deposit on the purchase price. The Asset Purchase agreement stipulated that the $1M deposit would be maintained until July 19, 2024, at which date, if the contemplated transaction was not consummated, through no fault of the Seller, the escrow would be released to the Seller by the escrow agent. The escrow deposit of $1M was released to the Seller, and recorded in Other Expense as a forfeited agreement cost in the three months and six months ended June 30, 2024. The Company and Seller are currently working towards a further amendment of the Asset Purchase Agreement and expect to achieve a positive outcome in the near term. The closing of the Asset Purchase Agreement is contingent on obtaining any further amendments and the necessary financing; there can be no assurance that the closing of the asset sale will occur.

On July 24, 2024, the Company, entered into a Supply Agreement (the “Supply Agreement”) with Stericare Solutions, LLC, a Texas limited liability company, (“Stericare”), pursuant to which Stericare agreed to purchase 520 million units of 10ml polypropylene (“PP”) Sologard syringes from the Company. The specific purchase price is confidential but revenues are expected in excess of $50M. Pursuant to the Supply Agreement, Stericare has agreed to purchase 520 million units of 10ml PP Sologard syringes in the following increments: 40 million units in the first year, and 120 million units every year for the remaining life of the Supply Agreement. The Supply Agreement has a five (5) year term targeted to commence in November 1, 2024 (the “Initial Term”). Upon expiration of the Initial Term, the Supply Agreement will automatically renew for additional one (1) year periods (each, a “Renewal Term”), unless a party gives the other party written notice of termination at least ninety (90) days prior to the end of the Initial Term or Renewal Term. The Agreement may be terminated by either party upon written notice to the other party if the other party breaches any material term or condition of this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice thereof. The Agreement may be terminated by either party upon written notice to the other party if the other party becomes insolvent, makes an assignment for the benefit of creditors, or a petition under any bankruptcy or insolvency Law is filed by or against such party and is not dismissed within 120 days. If either party is acquired by a competitor of the other party, then either party can terminate the Agreement with six (6) months written notice.

On July 12, 2023, The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Nasdaq Rule”). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until January 8, 2024, to regain compliance with the Rule. Subsequently, on January 16, 2024, the Company was provided an additional 180 calendar day compliance period, or until July 8, 2024, to demonstrate compliance. Pursuant to Nasdaq’s letter on July 9, 2024, the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq’s determination by July 16, 2024., the trading of the Company’s common stock and warrants will be suspended at the opening of business on July 18, 2024. The Company filed a hearing request before the deadline. In the interim, the Company’s common stock and warrants have remained listed on NASDAQ under its existing symbols, “STSS” and “STSW” while it awaits the results from the hearing on August 13, 2024.

On July 15, 2024, the Company held a Special Meeting of its stockholders. At the Meeting, 10,391,140 shares of the Company’s common stock were represented in person or by proxy out of the 15,670,898 shares outstanding and entitled to vote as of May 17, 2024, the record date for the Special Meeting.

The following three (3) proposals were each approved.

1.	The Company’s stockholders approved the amendment to the Company’s articles of incorporation to increase the authorized shares of common stock from 100,000,000 shares to 500,000,000 shares;

The Company’s stockholders approved a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within one year after stockholder approval is obtained, to amend the Company’s Articles of Incorporation to effect a reverse stock split of shares of the Company’s common stock, at a ratio of up to 1-for-8, with the exact ratio to be determined by the Company’s Board and included in a public announcement;

The Company’s stockholders approved a proposal for the issuance of securities in one or more non-public offerings where the maximum discount at which the securities will be offered will be equivalent to a discount not to exceed 20% below the market price of our common stock in accordance with Nasdaq Marketplace Rule 5635(d);

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The FMV adjustments, based on the trading price of outstanding warrants classified as liabilities, could impact the operating results in the reporting periods.

Nature of Business

Sharps Technology, Inc. (“Sharps” or the “Company”) continues to regard itself as a pre-revenue medical device company that has designed and patented various safety syringes and is seeking commercialization by manufacturing and distribution of its products. Through June 30, 2024, no substantial syringe product sales have occurred.

The accompanying unaudited condensed consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary, Safegard Medical, Kft. and Sharps Technology Acquisition Corp. collectively referred to as the “Company.” All intercompany transactions and balances have been eliminated.

The Company’s fiscal year ends on December 31.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak has adversely affected workforces, economies, and financial markets globally leading to an economic downturn in certain industries and countries. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds. Management continues to monitor the situation but has not experienced a significant disruption to its product development efforts.

Summary of Significant Accounting Policies

Our significant accounting policies are described in Note 2 of the accompanying condensed consolidated financial statements and further discussed in our annual financial statements included in our annual report on Form 10-K for the year ended December 31, 2023.

Off-Balance Sheet Arrangements

During the periods presented, we did not have any off-balance sheet arrangements as defined under Regulation S-K Item 303(a)(4).

Results of Operations – Three Months Ended June 30, 2024 and 2023.

	2024			2023			Change			Change %
Research and development	$	180,297			224,260		$	(43,964	)		20	%
General and administrative		1,740,803			2,308,075			(567,272	)		25	%
Other expense (income)		994,712			(40,079	)		1,034,791			258	%
FMV (gain) loss adjustment for derivatives		(822,130	)		90,108			(912,238	)		1,012	%
Foreign currency loss		8,646			23,461			(14,815	)		63	%
Net loss	$	2,102,327		$	2,605,825		$	(503,498	)		19	%

Revenue

The Company has not generated any significant syringe revenue to date.

Research and Development

For the three months ended June 30, 2024, Research and Development (“R&D”) expenses decreased to $180,297 compared to $224,260 for the three months ended June 30, 2023. The decrease of $43,964 was primarily due to lower depreciation expense and shift to increased manufacturing and reduced R&D activities in 2024 as compared to 2023.

General and Administrative

For the three months ended June 30, 2024, General and Administrative (“G&A”) expenses were $1,740,803 as compared to $2,308,075 for the three months ended June 30, 2023. The decrease of $567,272 was primarily attributable to: i) an increase in payroll and consulting fees of $84,000 from $741,402 in 2023 to $825,315 in 2024, primarily due to compensation increases and consulting services, ii) decrease in stock compensation expense, due to the timing of option awards, vesting and options valuations, of approximately $53,000 from $254,000 in 2023 to $201,000 in 2024, iii) decrease of $375,000 related to a contract settlement in the second quarter of 2023. Further, we had decreases in professional fees ($54,000), travel ($38,000), rent ($19,000), and other expenses ($48,000), patent and registration fees ($5,000), partially offset by higher computer costs ($14,000), board costs ($7,500) and insurance ($1,700).

Other expense (income)

Other was an expense of $994,712 for the three months ended June 30, 2024, compared to other income of $(40,079) for three months ended June 30, 2023. In 2024 and 2023 the Company generated interest income of $(5,288) and $(40,079), respectively. The totals in each period related to interest earned from cash balances held in interest bearing accounts. The Company’s initial syringe sale of $10,871, which approximated cost, was to a distributor in South America. The escrow deposit of $1M, relating to the Asset Purchase Agreement, was released to the Seller on July 19, 2024, under the terms of the agreement and recorded as forfeited agreement cost (See Note 14 to the Unaudited Condensed Consolidated Financial Statements).

FMV Adjustment for Derivatives

Certain Warrants require the Fair Market Value (“FMV”) to be remeasured at each reporting date while outstanding with recognition of the changes in fair value to other income or expense in the consolidated statement of operations. For the three months ended June 30, 2024 and 2023, the Company recorded a $822,130 FMV gain, net of a modification charge of $635,253 for the warrants exercised in connection with the Inducement Agreements and $90,108 FMV loss to reflect adjustments required for outstanding Warrants liabilities (See Notes 7 and 9 to the Unaudited Condensed Consolidated Financial Statements).

Results of Operations – Six Months Ended June 30, 2024 and 2023.

	2024			2023			Change			Change %
Research and development	$	377,736			558,148		$	(180,413	)		32	%
General and administrative		3,387,416			4,291,987			(904,570	)		21	%
Other expense (income)		975,688			(76,871	)		1,052,559			1,369	%
FMV (gain) loss adjustment for derivatives		(1,672,187	)		(93,977	)		(1,578,210	)		1,679	%
Foreign currency Loss		16,060			38,368			(22,308	)		58	%
Net loss	$	3,084,714		$	4,717,655		$	(1,632,941	)		35	%

Revenue

The Company has not generated any significant syringe revenue to date.

Research and Development

For the six months ended June 30, 2024, Research and Development (“R&D”) expenses decreased to $377,736 compared to $558,148 for the six months ended June 30, 2023. The decrease of $180,413 was primarily due to a shift to increased manufacturing and reduced R&D activities in 2024 as compared to the 2023 period which amounted to lower expenses of $88,000. In addition, depreciation expense decreased $92,000.

General and Administrative

For the six months ended June 30, 2024, General and Administrative (“G&A”) expenses were $3,387,416 as compared to $4,291,987 for the six months ended June 30, 2023. The decrease of $904,571 was primarily attributable to: i) increases in payroll and consulting fees of $365,000 from $1,311,326 in 2023 to $1,676,059 in 2024, primarily due to compensation increases and additional consulting fees, ii) decrease in stock compensation expense, due to the timing of option awards, vesting and option valuations, of approximately $312,000 from $637,547 in 2023 to $324,964 in 2024, iii) decrease in public company and investor relations costs of $223,000 from $358,000 to $135,000 in 2024 primarily due to lower offering costs in the 2024 period and reduced investor relations activities. Further, we had decreases due to lower: a) marketing costs ($280,000), b) travel ($49,000), c) insurance costs ($48,000) and d) rent ($57,000) e) general operating costs ($32,000) and a contract settlement of $375,000 in 2023. These decreases were partially offset by higher: a) computer costs ($30,000), b) board costs ($35,000), c) depreciation ($37,000) and d) patent and registration fees ($8,000).

Other expense (income)

Other was an expense of $(975,688) for the six months ended June 30, 2024, compared to income of $(76,871) for six months ended June 30, 2023. In 2024 and 2023 the Company generated interest income of $(24,312) and $(76,871), respectively. The interest income in each period was related to interest income earned from cash balances held in interest bearing accounts. In the second quarter of 2024, the Company’s initial syringe sale of $10,871, which approximated cost, was to a distributor in South America. The escrow deposit of $1M, relating to the Asset Purchase Agreement, was released to the Seller on July 19, 2024, under the terms of the agreement and recorded as a forfeited agreement cost (See Note 14 to the Unaudited Condensed Consolidated Financial Statements).

FMV Adjustment for Derivatives

Certain Warrants require the Fair Market Value (“FMV”) to be remeasured at each reporting date while outstanding with recognition of the changes in fair value to other income or expense in the consolidated statement of operations. For the six months ended June 30, 2024 and 2023, the Company recorded a $1,672,187 and $93,977 FMV gain to reflect adjustments required for outstanding Warrants liabilities. (See Notes 8 and 9 to the Unaudited Condensed Consolidated Financial Statements)

Liquidity and Capital Resources

At June 30, 2024 and December 31, 2023, we had a cash balance of $1,483,293 and $3,012,908, respectively. The Company had working capital of $978,400 and $1,145,569 as of June 30, 2024 and December 31, 2023, respectively. The decrease in our working capital was primarily due to use of cash in operations and investing discussed below offset by net proceeds from the Reg A and Inducement Offerings in May and June 2024 (See below and Note 7 to the Unaudited Condensed Consolidated Financial Statements).

The Company continues to assess liquidity requirements and plans to continue to seek funding through equity offerings and/or debt financing opportunities.

On May 31 and June 13, 2024, the Company entered into subscription agreements with certain institutional investors, pursuant to which the Company agreed to issue and sell to the investors 4,197,000 shares (the “Shares”) of Common Stock, par value $0.0001 per share of the Company at a price of $0.38 and received gross proceeds to the Company of $1.6M before expenses to the placement agent and other offering expenses of $298,000 with net proceed, after reflecting par value, have been recorded in Additional Paid in Capital of $1,296, 922. The shares issued in the offering were offered at-the-market under Nasdaq rules and pursuant to the Company’s Form 1-A (the “Offering Statement”), initially filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended on May 21, 2024, and qualified on May 30, 2024.

On May 30, 2024, the Company offered warrant inducements (the “Inducement Agreement”) to certain warrant holders (the “Warrant Holders”) which references the warrants registered for sale under both the registration statements on Form S-1 (file No. 333-263715) and/or the registration statement on Form S-1 (File No. 333-275011) (collectively, the “Registration Statements”) for up to a total of 10,998,524 warrants to purchase shares of the Company’s common stock, par value $0.0001 per share. Pursuant to the Inducement Agreement, the exercise price of the existing warrants was reduced from $0.64 per share to $0.33 per share. In addition, for each warrant that was exercised, as a result of the Inducement Agreement, the Company agreed to issue the Warrant Holders unregistered warrants with an exercise price of $0.45 per share (“Inducement Warrants”). In the aggregate,5,737,573 warrants were exercised as a result of the Inducement Agreement and accordingly, 5,737,573 Inducement Warrants were issued. The Company received gross proceeds of $1.9M before expenses to the placement agent and other expenses of $285,000. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $978,407 and with respect to the Inducement Warrants, a liability under ASC 815 was recorded in the amount of $693,064. Certain outstanding warrants, with an exercise price of $0.64, were reduced to $0.33 based on anti-dilution terms in the respective warrant agreements.

The first offering, the securities purchase agreement offering (the “Shelf Offering”) with institutional investors and the Company resulted in the Company receiving net proceeds from the Shelf Offering and the sale of pre-funded of approximately $2.5 million, includes the value of the pre-funded warrants recorded in APIC, net of $362,000 in fees relating to the placement agent and other offering expenses. The Shelf Offering was priced at the market under Nasdaq rules. In connection with the Shelf Offering, the Company issued 3,618,521 shares of common at a purchase price of $0.64 per unit and 800,000 pre-funded warrants at $0.639 per pre-funded warrants. The exercise price of the pre-funded warrants will be $0.001 per share.

The second offering, the securities purchase agreement offering (“Private Placement”) with institutional investors and the Company received net proceeds from the Private Placement of approximately $2.4 million, net of $354,000 in fees relating to the placement agent and other offering expense. In connection with the Private Placement, the Company issued: (i) 2,581,479 PIPE Shares (or PIPE Pre-Funded Warrants in lieu thereof) and (ii) PIPE Warrants (non-trading) to purchase 8,750,003 shares of our common stock, at a combined purchase price of $1.074 per unit (or $1.073 per pre-funded unit). The PIPE Warrants have a term of five and one-half (5.5) years from the issuance date and are exercisable for one share of common stock at an exercise price of $0.64 and adjusted to $0.33 at May 30, 2024. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $1.6 million and with respect to the PIPE Warrants recorded as a liability under ASC 815 of $985,204. On October 16, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Private Placement and on October 26, 2023 the S-1 went effective.

See Notes 8 and 10 to the Unaudited Condensed Consolidated Financial Statements

On February 3, 2023, we completed a securities purchase agreement (“Offering”) with institutional investors and received net proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, we issued 2,248,521 units at a purchase price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant (Offering Warrant) exercisable for one share of common stock at a price of $1.56 adjusted to $0.64 at September 29, 2023 and adjusted to $0.33 at May 30, 2024, based on anti-dilution terms in the warrants and a term of five years. The Offering Warrants have a term of five years from the issuance date (See Notes 8 to the Unaudited Condensed Consolidated Financial Statements).

On April 13, 2022, we completed our IPO which was declared effective by the SEC, and the Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022 and which closed on April 19, 2022. The net proceeds from the IPO were approximately $14.2 million of which $5,778,750 was attributed to the warrant liability (See Notes 8 and 10 to the Unaudited Condensed Consolidated Financial Statements).

Cash Flows

Net Cash Used in Operating Activities

The Company used cash of $3,528,676 and $4,131,000 in operating activities for the six months ended June 30, 2024 and 2023, respectively. The decrease in cash used of $602,324, was principally due to lower operating expenses during the six months ended June 30, 2024.

Net Cash Used in Investing Activities

For the six months ended June 30, 2024 and 2023, the Company used cash in investing activities of $1,019,355 and $342,525, respectively. In both periods cash was used to acquire or pay deposits for fixed assets, equipment and software. In 2024, the cash used for acquiring or paying deposits for fixed assets was $19,355 as compared to $342,525 in the 2023 period. In connection with the Asset Purchase agreement the Company paid a non-refundable deposit of $1M to be held in escrow under an agreeable escrow agreement as a deposit on the purchase price. Under the terms of the Asset Purchase Agreement, the escrow deposit was released to the Seller and the Company recorded a forfeited agreement cost in Other Expenses (See Note 14 to the Unaudited Condensed Consolidated Financial Statements).

Net Cash Provided by Financing Activities

For the six months ended June 30, 2024 and 2023, the Company provided cash from financing activities of $2,972,348 and $3,238,711, respectively. In the 2023 period, cash was provided from the Offering completed in February 2023 and in the 2024 period cash was provided from the exercise of pre-funded warrants and net proceeds from a Reg A offering and Warrant Inducements (See Note 7 to the Unaudited Condensed Consolidated Financial Statements).

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4).

Emerging Growth Company Status

We are an “emerging-growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company, we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging growth company.

We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of the initial public offering; (ii) the first fiscal year after our annual gross revenue are $1.07 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If, as a result of our decision to reduce future disclosure, investors find our common shares less attractive, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.

We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the aggregate amount of gross proceeds to us as a result of the IPO is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of internal controls that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

ITEM 1A. RISK FACTORS

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in the Form 10-K for the year ended December 31, 2023, any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in the Form 10-K for the year ended December 31, 2023. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sale of Unregistered Equity Securities

During the quarter ended June 30, 2024 the Company under Reg A, issued 4.1M unregistered but qualified shares of common stock.

Use of Proceeds

On April 13, 2022, our Registration Statement on Form S-1 (No. 333-263715) was declared effective by the SEC pursuant to which we issued and sold an aggregate of 3,750,000 units, each consisting of one share of common stock and two warrants, to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share and a term of five years. In addition, we granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number of shares included in the units sold in the offering, and/or additional warrants equal to 15% of the number of Warrants included in the units sold in the offering, in each case solely to cover over-allotments, which the Aegis Capital Corp. partially exercised with respect to 1,125,000 warrants on April 19, 2022. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates. There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus filed with the SEC on April 15, 2022. As of December 31, 2013, we have used the net proceeds from the IPO for working capital, acquisition of the Hungary facility and capital expenditures.

ITEM 6. EXHIBITS

Exhibit Number		Description

31.1*		Certification of Co-Chief Executive Officers (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Co-Chief Executive Officers (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 12th day of August 2024.

	SHARPS TECHNOLOGY, INC.

August 14, 2024	/s/ Robert M. Hayes
	Robert M. Hayes
	Chief Executive Officer and Director (Principal Executive Officer)

August 14, 2024	/s/ Andrew R. Crescenzo
	Andrew R. Crescenzo
	Chief Financial Officer
	(Principal Financial Officer)

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Robert M. Hayes, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Sharps Technology, Inc. (the Registrant);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	b)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	c)	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

	/s/ Robert M. Hayes
	Robert M. Hayes
	Chief Executive Officer (Principal Executive Officer)

Date: August 14, 2024

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Andrew R. Crescenzo, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Sharps Technology, Inc. (the Registrant);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and we have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	c)	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

	/s/ Andrew R. Crescenzo
	Andrew R. Crescenzo
	Chief Financial Officer (Principal Financial Officer)

Date: August 14, 2024

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, I, Robert M. Hayes, Chief Executive Officer of Sharps Technology, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

	(1)	Such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of Sharps Technology, Inc.

	/s/ Robert M. Hayes
	Robert M. Hayes
	Chief Executive Officer (Principal Executive Officer)

Date: August 14, 2024

A signed original of the certification required by Section 906 has been provided to Sharps Technology, Inc. and will be retained by Sharps Technology, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, I, Andrew R. Crescenzo, Chief Financial Officer of Sharps Technology, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

	(1)	Such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2024, fairly presents, in all material respects, the financial condition and results of operations of Sharps Technology, Inc.

	/s/ Andrew R. Crescenzo
	Andrew R. Crescenzo
	Chief Financial Officer (Principal Financial Officer)

Date: August 14, 2024

Cover - $ / shares	6 Months Ended
Cover - $ / shares	Jun. 30, 2024	Aug. 14, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41355
Entity Registrant Name	Sharps Technology, Inc.
Entity Central Index Key	0001737995
Entity Tax Identification Number	82-3751728
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	105 Maxess Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	(631)
Local Phone Number	574 -4436
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,590,509
Entity Listing, Par Value Per Share	$ 0.0001
Common Stock, $0.0001 Par Value [Member]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	STSS
Security Exchange Name	NASDAQ
Common Stock Purchase Warrants [Member]
Title of 12(b) Security	Common Stock Purchase Warrants
Trading Symbol	STSSW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 1,483,293	$ 3,012,908
Prepaid expenses and other current assets	162,298	116,508
Inventories, net (Note 3)	1,885,832	1,709,135
Current Assets	3,531,423	4,838,551
Fixed Assets, net of accumulated depreciation (Notes 4 and 5)	6,282,316	6,822,142
Other Assets (Notes 5 and 6)	118,482	128,575
TOTAL ASSETS	9,932,221	11,789,268
Current Liabilities
Accounts payable	878,048	794,107
Accrued and other current liabilities (Notes 12 and 14)	231,313	476,090
Warrant liability (Notes 7 and 9)	1,443,662	2,422,785
Total Current Liabilities	2,553,023	3,692,982
Deferred Tax Liability	162,000	162,000
Total Liabilities	2,715,023	3,854,982
Commitments and Contingencies (Note 14)
Stockholders’ Equity:
Preferred stock, $.0001 par value; 1,000,000 shares authorized; 1 share issued and outstanding
Common stock, $.0001 par value; 100,000,000, shares authorized; 28,590,509 shares issued and outstanding (2023: 15,274,457)	2,860	1,528
Additional paid-in capital	35,096,207	32,489,950
Accumulated other comprehensive income	351,848	591,812
Accumulated deficit	(28,233,717)	(25,149,004)
Total Stockholders’ Equity	7,217,198	7,934,286
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 9,932,221	$ 11,789,268

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common stock, shares issued	28,590,509	15,274,457
Common stock, shares outstanding	28,590,509	15,274,457

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue, net
Operating expenses:
Research and development	180,297	224,260	377,736	558,148
General and administrative	1,740,803	2,308,075	3,387,416	4,291,987
Total operating expenses	1,921,100	2,532,335	3,765,152	4,850,135
Loss from operations	(1,921,100)	(2,532,335)	(3,765,152)	(4,850,135)
Other income (expense)
Other (expense) income (Note 14)	(994,712)	40,079	(975,688)	76,871
FMV adjustment on contingent stock & warrants	822,130	(90,108)	1,672,187	93,977
Foreign currency	(8,645)	(23,461)	(16,060)	(38,368)
Total Other Income (Expense)	(181,227)	(73,490)	680,439	132,480
Net Loss	$ (2,102,327)	$ (2,605,825)	$ (3,084,713)	$ (4,717,655)
Net loss per share, basic	$ (0.10)	$ 0.22	$ (0.15)	$ (0.42)
Net loss per share, diluted	$ (0.10)	$ 0.22	$ (0.15)	$ (0.42)
Weighted average shares used to compute net loss per share, basic	21,557,563	11,655,936	20,106,750	11,193,740
Weighted average shares used to compute net loss per share, diluted	21,557,563	11,655,936	20,106,750	11,193,740

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net loss	$ (2,102,327)	$ (2,605,825)	$ (3,084,713)	$ (4,717,655)
Other comprehensive income:
Foreign currency translation adjustments gain/(loss)	(21,911)	73,786	(239,964)	344,859
Comprehensive loss	$ (2,124,238)	$ (2,532,039)	$ (3,324,677)	$ (4,372,796)

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022		$ 941	$ 24,733,306	$ 214,253	$ (15,307,366)	$ 9,641,134
Balance, shares at Dec. 31, 2022	1	9,407,415
Net loss					(2,111,830)	(2,111,830)
Share-based compensation charges			383,100			383,100
Foreign Currency Translation				270,983		270,983
Shares issued in Offering		$ 225	2,783,160			2,783,385
Shares issued in Offering, shares		2,248,521
Balance at Mar. 31, 2023		$ 1,166	27,899,566	485,236	(17,419,196)	10,966,772
Balance, shares at Mar. 31, 2023	1	11,655,936
Balance at Dec. 31, 2022		$ 941	24,733,306	214,253	(15,307,366)	9,641,134
Balance, shares at Dec. 31, 2022	1	9,407,415
Net loss						(4,717,655)
Balance at Jun. 30, 2023		$ 1,166	28,154,012	559,112	(20,025,021)	8,689,269
Balance, shares at Jun. 30, 2023	1	11,655,936
Balance at Mar. 31, 2023		$ 1,166	27,899,566	485,236	(17,419,196)	10,966,772
Balance, shares at Mar. 31, 2023	1	11,655,936
Net loss					(2,605,825)	(2,605,825)
Share-based compensation charges			254,446			254,446
Foreign Currency Translation				73,876		73,876
Balance at Jun. 30, 2023		$ 1,166	28,154,012	559,112	(20,025,021)	8,689,269
Balance, shares at Jun. 30, 2023	1	11,655,936
Balance at Dec. 31, 2023		$ 1,528	32,489,950	591,812	(25,149,004)	7,934,286
Balance, shares at Dec. 31, 2023	1	15,274,457
Net loss					(982,386)	(982,386)
Share-based compensation charges			126,387			126,387
Exercise of Pre-Funded Warrants		$ 40	356			396
Exercise of Pre-Funded Warrants, shares		396,441
Foreign Currency Translation				(218,053)		(218,053)
Balance at Mar. 31, 2024		$ 1,568	32,616,693	373,759	(26,131,390)	6,860,630
Balance, shares at Mar. 31, 2024	1	15,670,898
Balance at Dec. 31, 2023		$ 1,528	32,489,950	591,812	(25,149,004)	7,934,286
Balance, shares at Dec. 31, 2023	1	15,274,457
Net loss						(3,084,713)
Balance at Jun. 30, 2024		$ 2,860	35,096,207	351,848	(28,233,717)	7,217,198
Balance, shares at Jun. 30, 2024	1	28,590,509
Balance at Mar. 31, 2024		$ 1,568	32,616,693	373,759	(26,131,390)	6,860,630
Balance, shares at Mar. 31, 2024	1	15,670,898
Net loss					(2,102,327)	(2,102,327)
Share-based compensation charges			201,918			201,918
Exercise of Pre-Funded Warrants			2,686
Exercise of Pre-Funded Warrants, shares		2,985,038
Foreign Currency Translation				(21,911)		(21,911)
Exercise of Pre-Funded Warrants		$ 298	2,687			2,985
Registration A Offering		$ 420	1,296,502			1,296,922
Registration A Offering, shares		4,197,000
Warrant Inducements		$ 574	978,407			978,981
Warrant Inducements, shares		5,737,573
Balance at Jun. 30, 2024		$ 2,860	$ 35,096,207	$ 351,848	$ (28,233,717)	$ 7,217,198
Balance, shares at Jun. 30, 2024	1	28,590,509

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,102,327)	$ (982,386)	$ (2,605,825)	$ (2,111,830)	$ (3,084,713)	$ (4,717,655)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization					388,520	448,657
Stock-based compensation					328,305	637,547
FMV adjustment for Warrants	(822,130)		90,108		(1,672,187)	(93,977)
Escrow forfeited					1,000,000
Foreign exchange gain					(8,646)	30,141
Changes in operating assets:
Prepaid expenses and other current assets					(49,627)	(119,761)
Inventory					(255,439)	(769,088)
Other assets
Accounts payable and accrued liabilities					(174,889)	453,136
Net cash used in operating activities					(3,528,676)	(4,131,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of fixed assets or deposits paid					(19,355)	(342,525)
Escrow payment under agreement					(1,000,000)
Net cash used in investing activities					(1,019,355)	(342,525)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from offerings and warrant exercises					2,972,348	3,238,711
Net cash provided by financing activities					2,972,348	3,238,711
Effect of exchange rate changes on cash					46,068	(12,064)
NET INCREASE (DECREASE) IN CASH					(1,529,615)	(1,246,878)
CASH — BEGINNING OF YEAR		$ 3,012,908		$ 4,170,897	3,012,908	4,170,897	$ 4,170,897
CASH — END OF PERIOD	$ 1,483,293		$ 2,924,019		$ 1,483,293	$ 2,924,019	$ 3,012,908

Description of Business

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Description of Business

Note 1. Description of Business

Nature of Business and Going Concern

The Company’s fiscal year ends on December 31.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Use of Estimates

Cash and Cash Equivalents

Inventories

Fair Value Measurements

The Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating results at the reporting periods.

Level 1

Level 2

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Level 3

Fixed Assets

Impairment of Long-Lived Assets

There were no impairment losses recognized during the three and six months ended June 30, 2024 and 2023.

Purchased Identified Intangible Assets

Stock-based Compensation Expense

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Derivative Instruments

Foreign Currency Translation/Transactions

Comprehensive income (loss)

Basic and Diluted Loss Per Share

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

Income Taxes

Research and Development Costs

Research and development costs are expensed as incurred.

Contingencies

Recent Accounting Pronouncements

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 2. Summary of Significant Accounting Policies (continued)

The Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial statements.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Inventories

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

Inventories

Note 3. Inventories

Inventories, net consisted of the following at:

	June 30, 2024		December 31, 2023
Raw materials	$	302,107	$	254,461
Work in process		116,148		170,464
Finished goods		1,467,577		1,284,210
Total	$	1,885,832	$	1,709,135

Fixed Assets

6 Months Ended

Jun. 30, 2024

Property, Plant and Equipment [Abstract]

Fixed Assets

Note 4. Fixed Assets

Fixed assets, net, is summarized as follows as of:

	June 30, 2024			December 31, 2023

Land	$	246,075		$	260,460
Building		2,866,164			3,022,490
Machinery and Equipment		4,663,594			4,464,317
Computer Systems and Website & Other		290,662			290,661
Total Fixed Assets		8,066,495			8,037,928
Less: accumulated depreciation		(1,784,179	)		(1,215,786	)
Fixed asset, net	$	6,282,316		$	6,822,142

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Asset Acquisition

6 Months Ended

Jun. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Asset Acquisition

Note 5. Asset Acquisition

Safegard Medical, Kft

The relative fair value of the assets acquired and related deferred tax liability during 2022 was as follows:


Land	$	226,000
Building and affixed assets		2,648,000
Machinery		158,000
Inventory		32,000
Intangibles		64,712
Deferred tax liability		(192,000	)

Total	$	2,936,712

Other Assets

6 Months Ended

Jun. 30, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets

Note 6. Other Assets

Other assets as of June 30, 2024 and December 31, 2023 are summarized as follows:

	June 30, 2024		December 31, 2023

Intangibles, net		42,420		52,513
Other		76,062		76,062
Total Other assets	$	118,482	$	128,575

Stockholders’ Equity

6 Months Ended

Jun. 30, 2024

Equity [Abstract]

Stockholders’ Equity

Note 7. Stockholders’ Equity

Capital Structure

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 7 Stockholders’ Equity (continued)

Common Stock

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 7. Stockholders’ Equity (continued)

Warrants

	a)	In connection with the Inducement Warrants in the second quarter of 2024, the Company issued 5,737,573 non-trading Inducement Warrants as noted in Common Stock above. The Inducement Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The Inducement Warrants are recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024, the Company recorded a FMV gain adjustment of $293,684 (See Note 9).

	b)	In connection with one-year advisory services arrangement entered into in April 2023, the Company issued an aggregate of 630,000 warrants over the one-year term, at an exercise price of $1.56. During the three and six months ended June 30, 2024, the Company issued 0 and 135,000 warrants with a FMV of $8,590. During the three and six months ended June 30, 2023 the Company issued 135,000 warrants with a FMV of $19,836. The warrants have a three-year term and were fully vested on issuance. The FMV of the warrants issued in the six months ended June 30, 2024 was computed using the Black Scholes valuation model with the following assumptions: a) volatility of 33.46% to 81.62%, three-year term, risk free interest rate of 4.20% to 4.25% and 0% dividend rate. The FMV of the warrants issued in the three and six months ended June 30, 2023 was computed using the Black Scholes valuation model with the following assumptions: a) volatility of 37.45%, risk free interest rate of 3.58% and 0% dividend rate (See Note 9).

	c)	In connection with the Private Placement in September 2023, the Company issued 8,750,003 non-trading PIPE Warrants as a component of the Unit as noted in Common Stock above. The PIPE Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The PIPE Warrants are recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024, the Company recorded a FMV gain adjustment of $326,580, including the modification charge of $489,225 and $651,884, respectively (See Note 9).

	d)	In connection with the Offering in February 2023, the Company issued 2,248,521 non-trading warrants Offering Warrants as a component of the Unit as noted in Common Stock above. The Offering Warrants are classified as a liability based on ASC 815 and require remeasurement at each reporting period. The Offering Warrants were recorded at the FMV, computed using the Black Scholes valuation method. For the three and six months ended June 30, 2024 the Company recorded FMV gain adjustments of $139,844, including the modification charge of 146,028 referred to in Note 8 and $221,582, respectively For the three and six months ended June 30, 2023, the Company recorded a FMV gain (loss) of $(1,505) and $182,580 respectively (See Note 9).

	e)	In connection with the IPO in April 2022, the Company issued 7,500,000 warrants (Trading Warrants) as a component of the Units and 1,125,000 warrants to the underwriter (Overallotment Warrants), as noted in Common Stock above. The Trading and Overallotment Warrants were recorded at the FMV, being the trading price of the warrants, on the IPO effective date and the Warrants are classified as a Liability based on ASC 815. The Warrant liability requires remeasurement at each reporting period based on the trading price of the warrants. During the three and six months ended June 30, 2024, the Company recorded an FMV gain adjustment of $60,375 and $491,625, respectively. For the three and six months ended June 30, 2023, the Company recorded a FMV loss of $86,250 (See Note 9).

	(f)	The Company issued 235,295 Warrants (“Note Warrants”) to the note holders in connection with the repayment on the IPO on April 19, 2022. The Note Warrants, which are recorded at the FMV being the trading price of the warrants, are classified as a Liability based on ASC 815. The Note Warrants require remeasurement at each reporting period. During the three and six months ended June 30, 2024, the Company recorded a FMV gain of $1,647 and $13,412, respectively. For the three and six months ended June 30, 2023, the Company recorded a FMV loss of $2,353 (See Note 9).

	(g)	The underwriter received 187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price of $5.32 and are exercisable after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Scholes valuation model with the following assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend rate. The estimated FMV was classified as additional issuance costs.

Preferred Stock

6 Months Ended

Jun. 30, 2024

Equity [Abstract]

Preferred Stock

Note 8 Preferred Stock

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Warrant Liability

6 Months Ended

Jun. 30, 2024

Warrant Liability

Warrant Liability

Note 9. Warrant Liability

Schedule of Fair Value of Warrant

	June 30, 2024			June 30, 2023
Expected term (years)		3.90 to 5.59			3.00 to 3.86
Expected volatility		58.78% to 68.05	%		37.45% to 45.21	%
Risk-free interest rate		4.10% to 4.56	%		3.53% to 3.58	%
Dividend rate		0			0

The Warrant liability at June 30, 2024 and December 31, 2023 was as follows:

Schedule of Warrant Liability

	June 30, 2024		December 31, 2023
Trading and Overallotment Warrants	$	629,625	$	1,121,250
Note Warrants		17,176		30,588
Offering Warrants – February 2023		12,490		234,072
Offering Warrants – September 2023		384,991		1,036,875
Inducement Warrants – May 2024		399,380		-
Total Warrant Liability	$	1,443,662	$	2,422,785

The Warrants outstanding at June 30, 2024 and December 31, 2023 were as follows:

Schedule of Warrant Outstanding

	June 30, 2024		December 31,2023

Trading and Overallotment Warrants		8,812,500		8,812,500
Note Warrants		235,295		235,295
Offering Warrants – February 2023		189,349		2,248,521
Offering Warrants – September 2023		5,071,602		8,750,003
Inducement Warrants – May 2024		5,737,573		-
Warrants issued for services arrangement		630,000		495,000
Total Warrants Outstanding		20,676,319		20,541,319

Stock Options

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Stock Options

Note 10. Stock Options

A summary of options granted and outstanding is presented below.

	June 30, 2024
	Options			Weighted Average Exercise Price
Outstanding at Beginning of year		2,408,836		$	3.03
Granted		1,357,000			.28
Forfeited		(8,214	)		3.42
Outstanding at end of period		3,775,621		$	1.99

Exercisable at end of period		2,784,399		$	2.56

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 10 Stock Options (continued)

At June 30, 2024, the Weighted Average Remaining Contractual Life is forty-six months.

For the three and six months ended June 30, 2023, the Company recognized stock-based compensation expense of $234,610 and $617,711 which was recorded in general and administrative.

	June 30, 2024			June 30, 2023
Expected term (years)		2.66 to 3.06			2.77 to 3.25
Expected volatility		81.15% to 83.04	%		75.40% to 89.93	%
Risk-free interest rate		4.71% to 4.76	%		3.74% to 4.27	%
Dividend rate		0			0

Income Taxes

6 Months Ended

Jun. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Related Party Transactions and Balances

6 Months Ended

Jun. 30, 2024

Related Party Transactions and Balances

Note 12. Related Party Transactions and Balances

Fair Value Measurements

6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 13. Fair Value Measurements

As of June 30, 2024, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:

	Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	1,483,293		-		-	$	1,483,293

Total assets measured at fair value	$	1,483,293		-		-	$	1,483,293

Liabilities
Warrant liability	$	-	$	1,443,662		-	$	1,443,662

Total liabilities measured at fair value	$	-	$	1,443,662			$	1,443,662

As of December 31, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:


	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	3,012,908		-		-	$	3,012,908

Total assets measured at fair value	$	3,012,908		-		-	$	3,012,908

Liabilities
Warrant liability	$	-	$	2,422,785		—	$	2,422,785

Total liabilities measured at fair value	$	-	$	2,422,785		-	$	2,422,785

Commitments and Contingencies

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 14. Commitments and Contingencies

Contingencies

SHARPS TECHNOLOGY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Note 14 Commitments and Contingencies (continued)

Commitments

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	*Basis of Presentation* The accompanying condensed consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars. SHARPS TECHNOLOGY, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 Note 2. Summary of Significant Accounting Policies (continued)
Use of Estimates	*Use of Estimates* The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As of June 30, 2024, the most significant estimates relate to derivative liabilities and stock-based compensation.
Cash and Cash Equivalents	*Cash and Cash Equivalents* The Company considers all highly liquid investments purchased with an original or remaining maturity of six months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions. At June 30, 2024 and December 31, 2023, the Company had no cash equivalents.
Inventories	*Inventories* The Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess or obsolete inventories or they may be written off. At June 30, 2024, and December 31, 2023, inventory is comprised of raw materials, including packaging, work in process (components) and finished goods.
Fair Value Measurements	Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value. The Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating results at the reporting periods. Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment. Level 2 Level 2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates, maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed most similar to the security being priced; and determining whether a market is considered active requires management judgment. SHARPS TECHNOLOGY, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 Note 2. Summary of Significant Accounting Policies (continued) Level 3 Level 3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed Assets	*Fixed Assets* Fixed assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20 years, Machinery and Equipment – 3 - 10 years and Website and Computer Systems – 3 years. The expected life for Molds is based on the lesser of the number of parts that will be produced based on the expected mold capability or 5 years.
Impairment of Long-Lived Assets	*Impairment of Long-Lived Assets* Long-lived assets are reviewed for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There were no impairment losses recognized during the three and six months ended June 30, 2024 and 2023. Purchased Identified Intangible Assets The Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying value of indefinite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.
Stock-based Compensation Expense	*Stock-based Compensation Expense* The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur on a prospective basis. Stock-based compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. SHARPS TECHNOLOGY, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 Note 2. Summary of Significant Accounting Policies (continued)
Derivative Instruments	*Derivative Instruments* The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. At their issuance date and as of June 30, 2024, certain warrants (see Notes 7 and 9) were accounted for as liabilities as these instruments did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value is recognized in the Company’s condensed consolidated statements of operations.
Foreign Currency Translation/Transactions	*Foreign Currency Translation/Transactions* The Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the condensed consolidated statements of operations.
Comprehensive income (loss)	*Comprehensive income (loss)* Comprehensive income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary. Foreign currency translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance at June 30, 2024 and December 31, 2023. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments.
Basic and Diluted Loss Per Share	*Basic and Diluted Loss Per Share* The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the consolidated statements of operations. Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of June 30, 2024, there were 24,451,943 stock options and warrants that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented. SHARPS TECHNOLOGY, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 Note 2. Summary of Significant Accounting Policies (continued)
Income Taxes	*Income Taxes* The Company must make certain estimates and judgments in determining income tax expenses for financial statement purposes. These estimates and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision in a subsequent period. The provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities. The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in the period of such change.
Research and Development Costs	*Research and Development Costs* Research and development costs are expensed as incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
Contingencies	*Contingencies* Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.
Recent Accounting Pronouncements	*Recent Accounting Pronouncements* On August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company does not expect the pronouncement to have a material impact on the Company and will disclose the nature and reason for any elections that the Company makes. SHARPS TECHNOLOGY, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 Note 2. Summary of Significant Accounting Policies (continued) In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires disaggregated information about the effective tax rate reconciliation and additional information on taxes paid that meet a quantitative threshold. The new guidance is effective for public companies for annual reporting periods beginning after December 15, 2024, a, with early adoption permitted. The Company is currently evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements. The Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial statements. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Inventories (Tables)

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories, net consisted of the following at:

	June 30, 2024		December 31, 2023
Raw materials	$	302,107	$	254,461
Work in process		116,148		170,464
Finished goods		1,467,577		1,284,210
Total	$	1,885,832	$	1,709,135

Fixed Assets (Tables)

6 Months Ended

Jun. 30, 2024

Property, Plant and Equipment [Abstract]

Schedule of Fixed Assets, Net

Fixed assets, net, is summarized as follows as of:

	June 30, 2024			December 31, 2023

Land	$	246,075		$	260,460
Building		2,866,164			3,022,490
Machinery and Equipment		4,663,594			4,464,317
Computer Systems and Website & Other		290,662			290,661
Total Fixed Assets		8,066,495			8,037,928
Less: accumulated depreciation		(1,784,179	)		(1,215,786	)
Fixed asset, net	$	6,282,316		$	6,822,142

Asset Acquisition (Tables)

6 Months Ended

Jun. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of Fair Value of Assets Acquisition

The relative fair value of the assets acquired and related deferred tax liability during 2022 was as follows:


Land	$	226,000
Building and affixed assets		2,648,000
Machinery		158,000
Inventory		32,000
Intangibles		64,712
Deferred tax liability		(192,000	)

Total	$	2,936,712

Other Assets (Tables)

6 Months Ended

Jun. 30, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets

Other assets as of June 30, 2024 and December 31, 2023 are summarized as follows:

	June 30, 2024		December 31, 2023

Intangibles, net		42,420		52,513
Other		76,062		76,062
Total Other assets	$	118,482	$	128,575

Warrant Liability (Tables)

6 Months Ended

Jun. 30, 2024

Schedule of Warrant Liability

The Warrant liability at June 30, 2024 and December 31, 2023 was as follows:

Schedule of Warrant Liability

	June 30, 2024		December 31, 2023
Trading and Overallotment Warrants	$	629,625	$	1,121,250
Note Warrants		17,176		30,588
Offering Warrants – February 2023		12,490		234,072
Offering Warrants – September 2023		384,991		1,036,875
Inducement Warrants – May 2024		399,380		-
Total Warrant Liability	$	1,443,662	$	2,422,785

Schedule of Warrant Outstanding

The Warrants outstanding at June 30, 2024 and December 31, 2023 were as follows:

Schedule of Warrant Outstanding

	June 30, 2024		December 31,2023

Trading and Overallotment Warrants		8,812,500		8,812,500
Note Warrants		235,295		235,295
Offering Warrants – February 2023		189,349		2,248,521
Offering Warrants – September 2023		5,071,602		8,750,003
Inducement Warrants – May 2024		5,737,573		-
Warrants issued for services arrangement		630,000		495,000
Total Warrants Outstanding		20,676,319		20,541,319

Warrant [Member]

Schedule of Fair Value of Warrant

	June 30, 2024			June 30, 2023
Expected term (years)		3.90 to 5.59			3.00 to 3.86
Expected volatility		58.78% to 68.05	%		37.45% to 45.21	%
Risk-free interest rate		4.10% to 4.56	%		3.53% to 3.58	%
Dividend rate		0			0

Stock Options (Tables)

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Options Granted and Outstanding

A summary of options granted and outstanding is presented below.

	June 30, 2024
	Options			Weighted Average Exercise Price
Outstanding at Beginning of year		2,408,836		$	3.03
Granted		1,357,000			.28
Forfeited		(8,214	)		3.42
Outstanding at end of period		3,775,621		$	1.99

Exercisable at end of period		2,784,399		$	2.56

Schedule of Fair Value of Stock Option Awards

	June 30, 2024			June 30, 2023
Expected term (years)		2.66 to 3.06			2.77 to 3.25
Expected volatility		81.15% to 83.04	%		75.40% to 89.93	%
Risk-free interest rate		4.71% to 4.76	%		3.74% to 4.27	%
Dividend rate		0			0

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

As of June 30, 2024, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:

	Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	1,483,293		-		-	$	1,483,293

Total assets measured at fair value	$	1,483,293		-		-	$	1,483,293

Liabilities
Warrant liability	$	-	$	1,443,662		-	$	1,443,662

Total liabilities measured at fair value	$	-	$	1,443,662			$	1,443,662

As of December 31, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:


	Fair Value Measurements Using
	Level 1		Level 2		Level 3		Total

Assets
Cash	$	3,012,908		-		-	$	3,012,908

Total assets measured at fair value	$	3,012,908		-		-	$	3,012,908

Liabilities
Warrant liability	$	-	$	2,422,785		—	$	2,422,785

Total liabilities measured at fair value	$	-	$	2,422,785		-	$	2,422,785

Description of Business (Details Narrative) - USD ($)	Apr. 19, 2022	Jun. 30, 2024
Subsidiary, Sale of Stock [Line Items]
Working capital		$ 978,400
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from Issuance Initial Public Offering	$ 14,200,000

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Cash equivalents	$ 0		$ 0
Impairment losses
Stock Option and Warrants [Member]
Property, Plant and Equipment [Line Items]
Antidilutive shares amount	24,451,943
Building [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment asset useful life	20 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment asset useful life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment asset useful life	10 years
Website [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment asset useful life	3 years

Schedule of Inventories (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 302,107	$ 254,461
Work in process	116,148	170,464
Finished goods	1,467,577	1,284,210
Total	$ 1,885,832	$ 1,709,135

Schedule of Fixed Assets, Net (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total Fixed Assets	$ 8,066,495	$ 8,037,928
Less: accumulated depreciation	(1,784,179)	(1,215,786)
Fixed asset, net	6,282,316	6,822,142
Land [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	246,075	260,460
Building [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	2,866,164	3,022,490
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	4,663,594	4,464,317
Computer Systems and Website & Other [Member]
Property, Plant and Equipment [Line Items]
Total Fixed Assets	$ 290,662	$ 290,661

Fixed Assets (Details Narrative) - USD ($)	6 Months Ended
Fixed Assets (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 378,636	$ 445,252

Schedule of Fair Value of Assets Acquisition (Details) - Safegard Medical, Inc [Member]	Jul. 06, 2022 USD ($)
Business Acquisition [Line Items]
Land	$ 226,000
Building and affixed assets	2,648,000
Machinery	158,000
Inventory	32,000
Intangibles	64,712
Deferred tax liability	(192,000)
Total	$ 2,936,712

Asset Acquisition (Details Narrative) - USD ($)	1 Months Ended
Asset Acquisition (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2024	Jul. 06, 2022
Building [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives		20 years
Machinery and Equipment [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives		3 years
Machinery and Equipment [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives		10 years
Safegard Medical, Inc [Member]
Business Acquisition [Line Items]
Acquisition cost			$ 2,936,712
Transaction costs			$ 53,576
Intangible asset acquired, useful lives			5 years
Safegard Medical, Inc [Member] \| Building [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives			20 years
Safegard Medical, Inc [Member] \| Machinery and Equipment [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives			5 years
Safegard Medical, Inc [Member] \| Machinery and Equipment [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Fixed assets acquired, useful lives			10 years
Safegard Medical, Inc [Member] \| Share Purchase Agreement [Member]
Business Acquisition [Line Items]
Consideration paid in cash	$ 2,500,000
Safegard Medical, Inc [Member] \| Share Purchase Agreement [Member] \| Equity Option [Member]
Business Acquisition [Line Items]
Fair market value of common stock	183,135
Safegard Medical, Inc [Member] \| Share Purchase Agreement [Member] \| Common Stock [Member]
Business Acquisition [Line Items]
Fair market value of common stock	$ 200,000

Schedule of Other Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Intangibles, net	$ 42,420	$ 52,513
Other	76,062	76,062
Total Other assets	$ 118,482	$ 128,575

Stockholders’ Equity (Details Narrative) - USD ($)									1 Months Ended		3 Months Ended			6 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Jun. 13, 2024	May 31, 2024	May 30, 2024	Sep. 29, 2023	Feb. 03, 2023	Apr. 19, 2022	Apr. 13, 2022	Mar. 22, 2022	Sep. 30, 2023	Feb. 28, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	May 29, 2024	Dec. 31, 2023	Apr. 30, 2023	Apr. 14, 2022	Mar. 21, 2022	Apr. 18, 2019	Dec. 11, 2017
Subsidiary, Sale of Stock [Line Items]
Common stock, share authorized								100,000,000			100,000,000			100,000,000			100,000,000			50,000,000	50,000,000	20,000,000
Common stock par value											$ 0.0001			$ 0.0001			$ 0.0001					$ 0.0001
Preferred stock, shares authorized								1,000,000			1,000,000			1,000,000			1,000,000			10,000	10,000
Preferred stock, par value								$ 0.0001			$ 0.0001			$ 0.0001			$ 0.0001			$ 0.001	$ 0.001
Conversion of stock, description								Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation.
Gross proceeds				$ 5,600,000
Other offering expenses				$ 716,000
Additional paid in capital											$ 35,096,207			$ 35,096,207			$ 32,489,950		$ 9,000,000.0
Exercise of pre-funded warrants												$ 396
Warrants liability											1,443,662			$ 1,443,662			$ 2,422,785		$ 5,200,000
Dividend rate														0.00%	0.00%
Fair value adjustment of modification charge											$ 635,253
Warrants issued											20,676,319			20,676,319			20,541,319
Pre-funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise of pre-funded warrants, shares											2,900,000
Additional Paid-in Capital [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise of pre-funded warrants											$ 2,686	$ 356
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price																		$ 1.56
Issuance of warrants											0		135,000	135,000	135,000
Fair value adjustment of warrants											$ 8,590		$ 19,836	$ 8,590	$ 19,836
Warrants exercised						1,125,000
Aggregate warrants issued																		630,000
Volatility, minimum														33.46%
Volatility, maximum														81.62%
Expected term														3 years
Risk free interest rate, minimum														4.20%
Risk free interest rate, maximum														4.25%
Dividend rate											0.00%			0.00%
Volatility											37.45%			37.45%
Risk free interest rate											3.58%			3.58%
Inducement Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants											5,737,573
Fair value adjustment of warrants											$ 293,684			$ 293,684
Non Trading Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants				8,750,003					8,750,003	2,248,521
Fair value adjustment of warrants											139,844		(1,505)	221,582	182,580
Fair value adjustment of modification charge											146,028
Non Trading Warrants [Member] \| PIPE Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Fair value adjustment of warrants											326,580			651,884
Fair value adjustment of modification charge											489,225
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of units sold							3,750,000
Exercise price			$ 0.33	$ 0.64	$ 1.56	$ 5.32	$ 4.25
Nominal cost of warrant						$ 11,250
Warrants exercise price term							5 years
Fair value adjustment of warrants						228,750
Units description							each consisting of one share of common stock and two warrants, to purchase one share of common stock for each whole warrant
Description for offering shares							the Company granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number of shares included in the units sold in the offering, and/or additional warrants equal to 15% of the number of Warrants included in the units sold in the offering, in each case solely to cover over-allotments
Net proceeds from IPO						$ 14,200,000
Expected term						5 years
Dividend rate						0.00%
Risk free interest rate						2.77%
Warrants issued						187,500
Warrant exercisable date						Oct. 09, 2022
Volatility						93.47%
Trading Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants						7,500,000
Fair value adjustment of warrants											60,375		$ 86,250	491,625	86,250
Over-Allotment Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants						1,125,000
Note Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants						235,295
Fair value adjustment of warrants											$ 1,647			$ 13,412	$ 2,353
Subscription Agreements [Member] \| Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock par value	$ 0.0001	$ 0.0001
Number of units sold	4,197,000	4,197,000
Shares price	$ 0.38	$ 0.38
Gross proceeds	$ 1,600,000	$ 1,600,000
Other offering expenses	298,000	298,000
Additional paid in capital	$ 1,296,922	$ 1,296,922
Inducement Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock par value			$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			10,998,524
Exercise price			$ 0.33													$ 0.64
Inducement Agreement [Member] \| Warrant Holders [Member]
Subsidiary, Sale of Stock [Line Items]
Other offering expenses			$ 285,000
Additional paid in capital			$ 978,407
Exercise price			$ 0.64
Proceeds from Issuance of Warrants			$ 1,900,000
Nominal cost of warrant			$ 693,064
[custom:AdjustedOfWarrantsExercisePrice-0]			$ 0.33
Inducement Warrants [Member] \| Warrant Holders [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,737,573
Exercise price			$ 0.45
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price			0.33	0.64	$ 1.56
Issuance of warrants					2,248,521
Net proceeds from offering					$ 3,200,000
Shares issued price per share					$ 1.69
Warrants exercise price term					5 years
Offering expenses					$ 600,000
Units description					Each unit consisted of one share of common stock and one non-tradable warrant (“Offering Warrants”) exercisable for one share of common stock
Securities Purchase Agreement [Member] \| Pre-funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued price per share					$ 1.073
Securities Purchase Agreement [Member] \| PIPE Pre Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued price per share					$ 1.074
Securities Purchase Agreement [Member] \| Shelf Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price				$ 0.001
Issuance of warrants				3,618,521
Net proceeds from offering				$ 2,500,000
Net fees				$ 362,000
Shares issued price per share			0.33	$ 64
Securities Purchase Agreement [Member] \| Shelf Offering [Member] \| Pre-funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price				$ 0.639
Prefunded warrants				800,000
Securities Purchase Agreement [Member] \| Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Additional paid in capital				$ 1,600,000
Net fees				354,000
Net proceeds from the Private Placement				2,400,000
Fair value adjustment of warrants				$ 985,204
Securities Purchase Agreement [Member] \| Private Placement [Member] \| PIPE Pre Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price			$ 0.33	$ 0.64
Issuance of warrants				2,581,479
Warrants exercise price term				5 years 6 months

Preferred Stock (Details Narrative)	6 Months Ended
Preferred Stock (Details Narrative)	Jun. 30, 2024
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, voting rights	The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced from 50.1% at December 31, 2021 to 29.5%, effective with the IPO.

Schedule of Fair Value of Warrant (Details) - Warrant [Member]	Jun. 30, 2024	Jun. 30, 2023
Measurement Input, Expected Term [Member] \| Minimum [Member]
Expected term (in years)	3 years 10 months 24 days	3 years
Measurement Input, Expected Term [Member] \| Maximum [Member]
Expected term (in years)	5 years 7 months 2 days	3 years 10 months 9 days
Measurement Input, Option Volatility [Member] \| Minimum [Member]
Warrants liabilities measurement input	58.78	37.45
Measurement Input, Option Volatility [Member] \| Maximum [Member]
Warrants liabilities measurement input	68.05	45.21
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Warrants liabilities measurement input	4.10	3.53
Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Warrants liabilities measurement input	4.56	3.58
Measurement Input, Expected Dividend Rate [Member]
Warrants liabilities measurement input	0	0

Schedule of Warrant Liability (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Apr. 14, 2022
Class of Warrant or Right [Line Items]
Total Warrant Liability	$ 1,443,662	$ 2,422,785	$ 5,200,000
Trading and Overallotment Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrant Liability	629,625	1,121,250
Note Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrant Liability	17,176	30,588
Offering Warrants - February 2023 [Member]
Class of Warrant or Right [Line Items]
Total Warrant Liability	12,490	234,072
Offering Warrants - September 2023 [Member]
Class of Warrant or Right [Line Items]
Total Warrant Liability	384,991	1,036,875
Inducement Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrant Liability	$ 399,380

Schedule of Warrant Outstanding (Details) - shares	Jun. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	20,676,319	20,541,319
Trading and Overallotment Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	8,812,500	8,812,500
Note Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	235,295	235,295
Offering Warrants - February 2023 [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	189,349	2,248,521
Offering Warrants - September 2023 [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	5,071,602	8,750,003
Inducement Warrants - May 2024 [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	5,737,573
Warrants Issued for Services Arrangement [Member]
Class of Warrant or Right [Line Items]
Total Warrants Outstanding	630,000	495,000

Warrant Liability (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Warrant Liability (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Warrant Liability
Fair market value adjustment	$ 822,130	$ (90,108)	$ 1,672,187	$ 93,977
Fair value adjustment of modification charge	$ 635,253
Fair market value adjustment		$ 90,108		$ 93,977

Schedule of Stock Options Granted and Outstanding (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Stock option, beginning balance \| shares	2,408,836
Weighted average exercise price, beginning balance \| $ / shares	$ 3.03
Shares, options granted \| shares	1,357,000
Weighted average exercise price, options granted \| $ / shares	$ 0.28
Shares, options forfeited \| shares	(8,214)
Weighted average exercise price, options forfeited \| $ / shares	$ 3.42
Stock option, ending balance \| shares	3,775,621
Weighted average exercise price, ending balance \| $ / shares	$ 1.99
Stock option, exercisable \| shares	2,784,399
Weighted average exercise price, exercisable \| $ / shares	$ 2.56

Schedule of Fair Value of Stock Option Awards (Details)	6 Months Ended
Schedule of Fair Value of Stock Option Awards (Details)	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend rate	0.00%	0.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	2 years 7 months 28 days	2 years 9 months 7 days
Expected volatility	81.15%	75.40%
Risk-free interest rate	4.71%	3.74%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	3 years 21 days	3 years 3 months
Expected volatility	83.04%	89.93%
Risk-free interest rate	4.76%	4.27%

Stock Options (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Stock Options (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 11, 2017
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted average remaining contractual life			46 months
Granted options			5 years
Granted shares			1,357,000
Common stock par value	$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Options exercisable	$ 0.285		$ 0.285
Unrecognized stock-based compensation	$ 355,730		$ 355,730
Unvested stock options weighted average fair value	$ 0.93		$ 0.93
Recognized over a weighted-average period			11 months
Share based compensation	$ 201,918		$ 319,715
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation		$ 234,610	316,374	$ 617,711
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation			$ 3,341

Income Taxes (Details Narrative)	3 Months Ended		6 Months Ended
Income Taxes (Details Narrative)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate percentage	0.00%	0.00%	0.00%	0.00%

Related Party Transactions and Balances (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Officers and Directors [Member]
Accounts payable and accrued liabilities	$ 114,000	$ 32,974

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Assets
Cash	$ 1,483,293	$ 3,012,908
Total assets measured at fair value	1,483,293	3,012,908
Liabilities
Warrant liability	1,443,662	2,422,785
Total liabilities measured at fair value	1,443,662	2,422,785
Fair Value, Inputs, Level 1 [Member]
Assets
Cash	1,483,293	3,012,908
Total assets measured at fair value	1,483,293	3,012,908
Liabilities
Warrant liability
Total liabilities measured at fair value
Fair Value, Inputs, Level 2 [Member]
Assets
Cash
Total assets measured at fair value
Liabilities
Warrant liability	1,443,662	2,422,785
Total liabilities measured at fair value	1,443,662	2,422,785
Fair Value, Inputs, Level 3 [Member]
Assets
Cash
Total assets measured at fair value
Liabilities
Warrant liability
Total liabilities measured at fair value

Commitments and Contingencies (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 20, 2024	Sep. 30, 2022	Sep. 01, 2022	Aug. 01, 2022	Aug. 14, 2023	Jun. 30, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share based compensation								$ 328,305	$ 637,547
Alan Blackman [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs					$ 346,000
Medical benefit cost									$ 29,000
Share based compensation										$ 60,000
Due to related party						$ 53.000		53.000
Employment Agreement [Member] \| Alan Blackman [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Salaries and wages			$ 320,000	$ 256,000
Accrued bonus											$ 250,000
Payment for bonuses							$ 65,000
Employment Agreement [Member] \| Andrew R. Crescenzo [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold		$ 225,000
Payment for Incentive Fee		$ 18,750
Asset Purchase Agreement [Member] \| InjectEZ, LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire assets	$ 35,000,000
Escrow deposit	$ 1,000,000
Escrow deposit						$ 1,000,000		$ 1,000,000

Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Sharps Technology Charts.

Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

STSS Sharps Technology Inc

News Sharps Technology Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

STSS Sharps Technology Inc

News Sharps Technology Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen